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ABSTRACT 
 
Drug-loaded Gold Plasmonic Nanoparticles for      
In Vivo Therapy of Multidrug Resistance in Cancer  
and Rheumatoid Arthritis 
 
Hyung Joon Kim 
Graduate Program for Nanomedical Science 
The Graduate school 
Yonsei university 
 
Gold (Au) plasmonic nanoparticles (NPs) containing doxorubicin (DOX) 
for the treatment of multidrug resistance (MDR) in cancer were developed. To 
investigate the possibility of treating multidrug-resistant tumors with targeted 
chemo-photothermal treatment, in vitro and in vivo studies were conducted using a 
doxorubicin (DOX)-resistant DLD-1 cell line (DLD-1/DOX) and nude mice with 
xxiv 
 
human xenograft tumors, respectively. The chemo-photothermal treatment 
consisted of DOX-loaded-poly(lactic-co-glycolic acid, PLGA)-Au half-shell 
nanoparticles with targeting moieties of anti-death receptor-4 monoclonal antibody 
conjugated to the Au surface. The cells or xenografted tumors treated with 
nanoparticles were exposed to near infrared light for 10 min, which caused an 
increase in temperature to 45 °C. Chemo-photothermal treatment resulted in a large 
reduction in the rate of tumor xenograft growth on DLD-1/DOX tumor-bearing 
mice with a much smaller dose of DOX than conventional DOX chemotherapy. 
These results demonstrate that targeted chemo-photothermal treatment can provide 
high therapeutic efficacy and low toxicity in the treatment of multidrug-resistant 
tumors.  
RGD-attached gold (Au) plasmonic nanoparticles (NPs) containing 
methotrexate (MTX) for the treatment of rheumatoid arthritis (RA) were also 
developed. The MTX is the most widely used disease modifying anti-rheumatic 
drug (DMARD) for the treatment of RA, and RGD peptide (arginine-glycine-
aspartic acid) is a targeting moiety for inflammation. Upon near-infrared (NIR) 
irradiation, heat is locally generated due to Au half shells, and the drug release rate 
is enhanced, delivering heat and drug to the inflamed joints simultaneously. RA is 
a chronic inflammatory disease characterized by synovial inflammation in multiple 
joints within the penetration depth of NIR light. When combined with NIR 
irradiation, these nanoparticles containing a much smaller dosage of MTX (1/930 
of MTX solution) showed greater therapeutic effects than that of a conventional 
xxv 
 
treatment with MTX solution in collagen-induced arthritic (CIA) mice. This novel 
drug delivery system is a good way to maximize therapeutic efficacy and minimize 
dosage-related MTX side effects in the treatment of RA. Furthermore, these 
multifunctional nanoparticles could be applied to other DMARDs for RA or other 
inflammatory diseases.  
Similar results were obtained using MTX-loaded PLGA gold (Au)/iron 
(Fe)/gold (Au) half-shell nanoparticles conjugated with RGD, which can be applied 
for magnetic targeted chemo-photothermal treatment, and in vivo multimodal 
imaging of RA. The Fe half-shell layer embedded between the Au half-shell layers 
enables in vivo T2
 
-magnetic resonance (MR) imaging in addition to NIR 
absorbance imaging. Furthermore, the delivery of the nanoparticles to the 
inflammation region in CIA mice, and their retention can be enhanced under 
external magnetic field. When combined with consecutive NIR irradiation and 
external magnetic field application, these nanoparticles provide enhanced 
therapeutic effects with an MTX dosages of only 0.05% dosage compared to free 
MTX therapy for the treatment of RA. 
 
 
 
Keywords: Drug-loaded Au plasmonic nanoparticles, Drug-loaded Au/Fe/Au 
plasmonic nanoparticles, chemo-photothermal treatment, photothermally controlled 
drug delivery, multidrug resistance in cancer, rheumatoid arthritis 
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Chapter 1.  
Introduction 
 
 
 
 
 
1.1. Overview of multifunctional nanoparticles 
 
1.1.1. Multifunctional nanoparticles 
 
Nanoparticles are particles with 1 ~ 100 nm in size. These nanoparticles have 
shown size dependent physical and chemical properties such as optical, catalytic, 
magnetic, electrochemical, and thermodynamic, which are different from the same 
composition of bulk materials. A variety of nanoparticles made of different 
materials such as gold nanoparticles, magnetic nanoparticles, quantum dots, 
upconversion nanoparticles, carbon nanotubes, and polymeric particles have been 
fabricated and used in many scientific fields including physics, chemistry, material 
sciences, and medicine [1]. Especially, the application of nanoparticles to medicine, 
known as nanomedicine, uses the precisely engineered nanoparticles to develop 
novel therapeutic and diagnostic of several diseases. Exploring these unique 
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properties of nanoparticles can overcome some hurdles found in conventional 
therapeutic agents and diagnostic tools.  
 
• Physical properties and applications of various nanoparticles 
 
1) Gold nanoparticles  
 
The most common type of gold nanoparticles is gold nanospheres, and their 
unique optical properties is localized surface plasmon resonance (LSPR), in which 
conduction band electrons in gold nanospheres oscillate coherently with incident 
light at specific frequency [2]. Part of the absorbed energy is emitted in the form of 
scattered light, which then application the optical imaging and the rest of the 
energy is converted into heat. Gold nanospheres cannot apply to in vivo 
applications, because gold nanospheres have absorption peak at around 520 nm 
wavelength. For in vivo applications, the absorption peak should match within the 
biological optical window of human tissues (650 ~ 900 nm), in which minimal 
optical absorption by intrinsic chromophores, such as hemoglobin (< 650 nm) and 
water (> 900 nm), resulting in maximal penetration of light into biological tissues 
[3]. The absorption spectrum of gold nanoparticles can be tuned through geometry 
modification. For example, gold nanorods, LSPR occurs in two directions; along 
the short- and the long-axes [4]. Other gold nanostructures such as gold nanoshells 
and gold nanocages have tunable surface plasmon resonance peak with changing 
their sizes and thickness of walls (Figure 1a). Aggregated gold nanospheres also 
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exhibit NIR absorption due to the coupled plasmon resonance. This property can be 
applied to photothermal therapy in various diseases. 
Scattered light at LSPR frequency of gold nanoparticles uses to optical 
imaging. In addition, gold nanoparticles enhance local electromagnetic fields 
due to the LSPR. Therefore, the signals of SERS (surface-enhanced Raman 
scattering) or fluorophore reporters bound to a gold surface can be dramatically 
increased [5]. In in vivo applications, gold nanoparticles are good contrast agents 
for optical coherence tomography (OCT), computed tomography (CT), 
photoacoustic (PA) imaging, and near-infrared (NIR) optical imaging as well as 
photothermal therapy agents at the NIR region [6]. 
 
2) Magnetic nanoparticles  
 
Magnetic nanoparticles are mainly consisted of iron oxides (magnetite or 
maghemite). When the size of magnetic particles is smaller than the magnetic 
domain wall width (usually less than 100 nm), the particles will contain only a 
single magnetic domain with the magnetic moment from all unpaired electrons 
coupled in one direction [7]. Thermal fluctuation leads to flip of the coupled 
magnetic moment among several crystal axes of the nanoparticle. The flipping rate 
increases until no net magnetization can be observed as the particle size decreases. 
These magnetic nanoparticles which have limited size are called 
superparamagnetic nanoparticles. Usually, the size of superparamagnetic iron oxide 
nanoparticles is between 20 and 25 nm at room temperature [7]. Upon an external 
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magnetic field is applied, the magnetic moment of the superparamagnetic 
nanoparticles will align along the magnetic field and reach saturation at relatively 
low magnetic field strength. In biomedical application, magnetite and maghemite 
nanoparticles are the most well known magnetic nanoparticles due to their 
excellent biocompatibility. Nanoparticles of materials that have higher saturation 
magnetization have also been fabricated (Figure 1b). 
Superparamagnetic iron oxide nanoparticles (SPIOs) were used as a T1 or T2
 
 
contrast agents for MRI, and exhibited clinical tumor detection application [8]. 
Magnetic nanoparticles also show hyperthermia induction and magnetic targeting. 
Magnetic nanoparticles can generate heat under an oscillating magnetic field (100 
kHz to 1 MHz), which enables the hyperthermia for cancer therapy [9]. Magnetic 
targeting has been used in in vitro such as cell separation, gene transfection as well 
as controlled delivery of therapeutic agents in in vivo system [10]. 
3) Quantum dots  
 
Quantum dots (QDs) is fluorescence-emitting semiconductor nanoparticles, 
which usually used in optical imaging. Most QDs are consisted of binary alloys 
such as CdSe or InP semiconductor materials. Owing to quantum confinement of 
valence electrons at nanometer scales, QDs have shown fluorescence emission at 
various size and composition (Figure 1c) [11]. As shown in Figure 1c, the emission 
peak is red-shifts as the size of QDs increases. QDs have a narrow emission peak 
and an absorption peak from UV to visible wavelengths range as compared to 
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organic fluorophores. So, multicolor fluorescence imaging can be achieved in in 
vitro and in vivo systems and the toxicity of QDs was also investigated [12]. 
 
4) Upconversion nanoparticles  
 
An upconversion nanoparticles (~ 10 nm) has been studied after advances in 
rare-earth nanoparticle synthesis [13]. The upconversion nanoparticles have unique 
optical properties because they can absorb infrared radiation and emit photons at 
visible region. This upconversion process is achieved through continuous 
excitation of valence electrons of lanthanide ions by photon absorption or energy 
transfer from nearby excited lanthanide ions [14]. These upconversion 
nanoparticles are composed of a host material doped with lanthanide ions which act 
as sensitizers (Yb3+) and activators (Er3+, Tm3+, and Ho3+
Upconversion nanoparticles are excited at 980 nm using a InGaAs diode 
laser system and the low-power NIR excitation makes upconversion nanoparticles 
useful for in vivo optical imaging. Coupling upconversion nanoparticles with 
photosensitizers showed the ability to photodynamic therapy of cancer [16]. 
). Similar to QDs, 
upconversion nanoparticles have an narrow emission spectrum that can be tuned by 
changing host materials, doping density, and sensitizer ions (Figure 1d) [15].  
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5) Other inorganic nanoparticles  
 
There are various inorganic nanoparticles, including silica nanoparticles [17], 
calcium phosphate nanoparticles [18], hafnium oxide nanoparticles [19], and 
carbon nanotubes. Silica and calcium phosphate nanoparticles do not exhibit 
unique quantum mechanical properties. However, these nanoparticles have 
biocompatibility, convenient size tuning, various conjugation chemistry, and 
versatile cargo loading strategy as well as used for carriers of drug molecules, 
genes, and imaging contrast agents [20-22]. Silica nanoparticles with organic dyes 
and radioactive iodide, known as Cornell dots or C dots, have also been approved 
for clinical trials.  
Carbon nanotubes are formed from coaxial graphite sheets (< 100 nm) rolled 
up into cylinders and have two types; single- or multi-walled nanotubes. They have 
excellent strength and electrical properties, and can be water soluble by surface 
modification. Single-walled carbon natubes can be used as photothermal therapy 
agent, optical imaging agents, and drug carriers [23]. 
 
6) Polymeric particles  
 
Polymeric particles have several advantages, such as (a) encapsulation of 
various drugs and release them over prolonged periods or shot periods, (b) 
modification of surfaces with targeting ligands or antibody, and (c) excellent 
stability in both in vitro and in vivo system. Biodegradable polymers such as 
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poly(glycolic acid), poly(lactic acid) (PLA), and their copolymers have been used 
for various drug delivery applications [24]. Copolymers of hydrophobic polymers 
and hydrophilic polymers such as poly(ethylene glycol) (PEG), PEO, and 
poly(propylene oxide) (PPO) are explored to synthesize self-assembled therapeutic 
carriers [25]. Responsive polymers, which respond to an external stimulus such as 
pH, temperature, and electromagnetic radiation are also studied for drug delivery 
[26-27]. 
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Figure 1. Physical properties of various nanoparticles [28]. (a) Gold nanocage 
exhibits tunable surface plasmon resonance peak. (b) Magnetic nanoparticles 
fabricated by doping iron oxide with various magnetic ions. (c) Quantum dots 
exhibits size-tunable fluorescence emission. (d) Emission spectra of upconversion 
nanoparticles with different sensitizer and activator ions. Abbreviations: CLIO, 
cross-linked iron oxide; MEIO, magnetism-engineered iron oxide; MRI, magnetic 
resonance imaging; TEM, transmission electron microscopy; ABS, absorption 
spectrum; EM, emission.  
- 9 - 
 
Multifunctional nanoparticles (MFNPs) composed of inorganic materials 
such as metal, semiconductor, silica and rare earth minerals shows unique optical, 
electric, magnetic, and plasmonic properties due to the quantum mechanical effects 
originated from nanometer scale [29]. Inorganic nanoparticles have multifunction 
in nature. For example, gold nanoparticles used as a contrast agents for optical 
imaging, photoacoustic (PA) imaging, and computed tomography (CT) [30]. Also, 
gold nanoshells and nanocages can be applied for photothermal therapy upon near-
infrared (NIR) laser irradiation as well as NIR optical imaging [31-32]. MFNPs can 
achieve combined effects which cannot obtain in mono functional nanoparticles; 
for example, a quantum dot can show high fluorescence but it cannot show 
magnetic property [33].  
The schemes of MFNPs are combining two or more imaging functions for 
multimodal imaging, integrating drug delivery with imaging for image-guided drug 
delivery, and combining drug delivery with thermal treatments for synergistic 
effects [28].  
For realization of combined effects of MFNPs, it is important to explore 
surface chemistry and surface modification techniques. Small molecules, such as 
therapeutic agents, dyes, antibody, and targeting ligand can be bound to the 
nanoparticles surface via well-established surface chemistry. Liposome or micelle 
encapsulation and mesoporous silica coating, and layer-by-layer assembly of 
biopolymers methods can apply to decorate nanoparticles, results in multifunctions. 
Therefore, various MFNPs can be fabricated by combining nanoparticles and small 
molecules (Figure 2). 
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Figure 2. Schematic diagram of multifunctional nanoparticles [28]. Four typical 
coatings explored for nanoparticles are (a) liposome or micelle encapsulation, (b) 
mesoporous silica coating, (c) layer-bylayer assembly, and (d) surface modification. 
Abbreviations: GNP, gold nanoparticles; HfO, hafnium oxide nanoparticles; MNP, 
magnetic nanoparticles; QD, quantum dot; UCNP, upconversion nanoparticles. 
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The synthesis of most inorganic MFNPs involves two steps; nucleation and 
crystal growth by deposition of atoms on the crystal surface. Iron oxide 
nanoparticles, QDs, and upconversion nanoparticles can be synthesized using 
coprecipitation or thermal decomposition of precursor compounds with capping 
molecules and solvents [13, 34-36]. The common synthetic methods for integration 
of different nanoparticles or the combination of nanoparticles with small molecules 
are shown in Table 1. 
 
Table 1. Synthesis methods for MFNPs [28]. 
 
Abbreviations: PEG, poly(ethylene glycol); PEI, poly(ethyl enimine); QD, 
quantum dot; SPIO, superparamagnetic iron oxide nanoparticle; TRITC, 
tetramethylrhodamine isothiocyanate. 
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1.1.2. Applications in nanomedicine 
 
An important application of multifunctional nanoparticles (MFNPs) is 
medicine. MFNPs have various functions in medicine applications such as (a) 
contrast agents for multimodality imaging, (b) image-guided drug delivery, (c) 
magnetic drug targeting, and (d) drug delivery in combination with thermal therapy. 
 
(a) Contrast agents for multimodality imaging 
 
Usually, imaging technique is effective only for examining one specific 
disease due to the limitations in resolution, specificity, sensitivity, time and cost.  
However, multimodality imaging which merging various imaging techniques into 
one platform have ability to overcome these hurdles and can provide better disease 
management. The nanoparticles designed for MRI, NIR optical imaging, and PA 
imaging can be easily conjugated with small-molecule imaging moieties, including 
SERS reporters, MRI contrast agents (Gd3+ or Mn2+
These multimodality imaging nanoprobes can provide local as well as high-
resolution images than that of just one imaging probe. For example, gold 
nanospheres were functionalized with both a Raman molecular tag, trans-1,2-bis(4-
pyridyl)-ethylene, and an MRI T
), fluorophores and radiotracers. 
1 agent, DOTA-Gd3+. This fabricated 
multimodality imaging nanoprobes enable MRI, PA imaging, and Raman imaging 
(Figure 3) [37]. 
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Figure 3. MFNPs for multimodality imaging [37]. (a) Schematic diagram of 
trimodality nanoparticle for brain tumor imaging. (b) Trimodality detection of brain 
tumors in living mice. (c) Raman-guided intraoperative surgery. Abbreviations: 
CD11b, cluster of differentiation molecule 11b; GFP, green fluorescent protein. 
 
(b) Image-guided drug delivery 
 
It is important to deliver drug into the entire tumor at concentrations above a 
therapeutic threshold to success the cancer chemotherapy. A standard 
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chemotherapy would be effective only during a narrow therapeutic window in 
some patients. However, image-guided drug delivery simultaneously enables 
guiding disease interventions and effective drug delivery to the disease site. For 
example, siRNA conjugated to dextran-coated SPIOs as well as attachment of NIR 
dye, Cy 5.5 have been used to image in vivo siRNA delivery (Figure 4) [38]. The 
accumulation of siRNA at the tumor region was visualized with both in vivo NIR 
optical imaging and MRI imaging. 
 
Figure 4. Image-guided siRNA delivery [38]. (a) Schematic diagram of the siRNA 
carrier with MRI/NIR modalities (MN-NIRF-siRNA). MN (magnetic nanoparticles) 
core and Cy5.5 can be detected with MRI and NIRF imaging, respectively. (b) In 
vivo MRI of mice bearing subcutaneous LS174T human colorectal adenocarcinoma 
(arrows). (c) NIRF imaging of the mouse after injection of MN-NIRF-siRNA (top: 
white light, middle: NIRF, bottom: color-coded overlay). 
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(c)  Magnetic drug targeting 
 
The ability to actively deliver drugs in in vivo system has been achieved by 
magnetic targeting property of MFNPs. Therapeutic agents attached to magnetic 
nanoparticles can be accumulated to local disease region under magnetic guidance 
after proper design of the externally applied magnetic field [39-40]. In the 1978, 
magnetic targeting in in vivo system was first demonstrated using magnetic 
albumin microspheres (clusters of albumins with 10 ~ 20 nm in diameter of 
magnetic particles) [41]. Selective targeting of magnetic albumin microspheres 
containing doxorubicin to Yoshida sarcoma-bearing rat were also demonstrated in 
1983 [42].  
Recent advances in nanotechnology have accelerated the development of 
magnetic nanoparticles. Magnetic nanoparticles have advantages than microspheres 
such as deep tumor penetration, better biocompatibility, and optimum 
biodistribution. Several types of magnetic nanoparticles, including micelles-, 
liposomes-, and mesoporous silica-coated SPIOs, have been shown magnetic 
targeting of drugs in in vivo system [43]. Magnetic targeting could be explored 
using an implanted magnetic stent after injection of paclitaxel-loaded magnetic 
nanoparticles [44]. Electrostatic interaction of positively charged magnetic lipid 
nanoparticle with negatively charged siRNA could also be applied to magnetically 
guided gene therapy [10]. 
In another study, magnetically targeted SPIOs/lentiviral vectors were used to 
deliver enhanced green fluorescent protein (eGFP) plasmid to mouse aorta ex vivo 
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and SPIOs/lentiviral vectors-trasnsduced endothelial cells could be also located in 
injured carotid artery by external magnetic field (Figure 5) [45].  
 
 
 
Figure 5. Magnetic targeting of lentiviral vectors and positioning of transduced 
cells under external magnetic field [45]. (a) The magnetic flux density of magnets 
placed beside a vessel. (b) Magnetic targeting of SPIOs/lentiviral vectors to aorta 
during ex vivo perfusion. (c) In vivo location of SPIOs/lentiviral vectors –
transduced HUVECs (human umbilical vein endothelial cells) at injured carotid 
artery by external magnetic field. 
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(d) Drug delivery in combination with thermal therapy 
 
Hyperthermia (thermotherapy) has been widely used to cancer therapy and 
local heat generation can enhance the extravasation of drug-loaded nanoparticles 
from tumor vessels [46]. Conventional chemotherapy can be combined with 
thermal therapy, leading to synergistic effect than the sum of independent therapy. 
Therefore, drug-loaded gold nanoparticles or magnetic nanoparticles provide 
effective combined thermal and chemotherapy of cancer. 
A controlled drug release can be enabled by combination therapy. High 
concentration of drug in target region can be achieved by local heat-induced burst 
drug release. For example, heat generation under oscillating AC (alternating current) 
magnetic field would destroy the magnetite shell of drug-loaded magnetite 
shell/silica cores nanoparticles, resulting in release of drug stored in the silica 
matrix [47]. In another study, mesoporous silica sealed with thermosensitive 
nanovalves which encapsulated in zinc-doped iron oxide nanocrystals and 
doxorubicin (DOX) was fabricated. Heating of zinc-doped iron oxide nanocrystals 
after oscillating AC magnetic field led to rapid DOX release (Figure 6) [48]. 
Gene delivery has also been realized by local heat generation. Heat is 
applied to dextran-coated SPIOs conjugated with double-strand DNA (dsDNA). 
Increasing temperature induces releasing single-strand DNA oligo from dsDNA 
[49]. Similarly, endolysosomal escape of siRNA from a hollow gold nanoshell 
conjugated with thiolated siRNA after NIR laser irradiation could also studied. 
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Further study shows that p65 siRNA photothermal transfection and irinotecan 
treatment exhibit tumor suppression in in vivo [50]. 
 
Figure 6. Combined thermal and chemotherapy system [48].  
(a) Schematic diagram of magnetic-core silica nanoparticles (MCSN) for 
magnetically triggered drug release system. MCSN are synthesized by coating 
zinc-doped iron oxide nanocrystals (1) with mesoporous silica (2). The base of the 
molecular machine is inserted to the template silica (3). The drug (DOX) is then 
loaded into the template silica and capped with thermosensitive nanovalves (4) to 
complete the magnetically triggered drug release system. DOX release can be 
realized by heat generation under oscillating AC magnetic field (5). (b) 
Fluorescence microscope images (1, 3, and 5) and differential interference contrast 
(DIC) overlaid images (2, 4, and 6). Images 5 and 6 show DOX release after a 5 
min oscillating AC magnetic field application (Color : green, fluorescently labeled 
MCSN; red, DOX; yellow, merged green and red). (c) Quantification of cell death 
after various treatments shown in b. 
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1.2. Gold (Au) plasmonic nanoparticles for cancer 
photothermal therapy and optical imaging 
 
When Au plasmonic nanoparticles (NPs) absorb light, the oscillating 
electromagnetic field of the light generates polarization of the conduction band 
electrons on the surface of the nanoparticles, and the polarized electrons move 
through coherent oscillations with respect to the positive ions in the metal. These 
oscillations are called as surface plasmon resonance (SPR) (Figure 7a) [4, 51]. The 
excited surface plasmon electrons relax in two ways; 1) scattering : emit the light 
which has the same energy of incident light, 2) absorption : transfer the absorbed 
energy to the form of thermal energy.  
Au plasmonic NPs that have significant absorption in the tissue optical 
window (650 ~ 900 nm), which is also known as NIR window, are promising NIR 
imaging or agent. In the NIR window region, light absorption was minimized by 
hemoglobin (< 650 nm) and water (> 900 nm) (Figure 7b) [3]. Therefore, NIR 
imaging can enable using Au plasmonic NPs due to the combined NIR light 
scattering and NIR window.  
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Figure 7. (a) Surface plasmon resonance (SPR) of spherical gold nanoparticles 
(AuNPs) and gold nanorods (AuNRs) [4,51]. (b) NIR optical window (650 ~ 900 
nm) [3]. 
 
Near infrared (NIR) resonant nanomaterials, including Au nanoshell particles, 
Au nanorods, Au nanocages, and carbon nanotubes, were studied recently for 
cancer treatment because they strongly absorb NIR light and produce localized 
cytotoxic heat upon NIR irradiation [52]. Among these NIR resonant nanomaterials, 
Au plasmonic NPs show unique size and shape dependent optical and photothermal 
properties originated from localized surface plasmon resonance (LSPR), an 
electromagnetic mode related with the collective oscillation of free electrons in 
conduction bands of Au plasmonic NPs [2]. After excitation of LSPR by NIR laser, 
electron–electron and photon–electron interactions generate heat, which can be 
used to photothermal treatment, or to release drug in thermosensitive drug-delivery 
systems. When this photothermal treatment is combined with targeted delivery and 
chemotherapy, therapeutic efficacy is enhanced significantly [53-58]. The synthesis 
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of Au plasmonic NPs with controlled size and morphology led to the fabrication of 
various Au plasmonic nanostructures such as gold nanoshells (AuNSs), gold 
nanorods (AuNRs), hollow gold nanospheres (HAuNSs), and gold nanocages 
(AuNCs). These Au plasmonic nanostructures exhibit well-defined SPR absorption 
properties from visible to the NIR region [52].   
 
 
1) Gold nanoshells (AuNSs) 
 
Double stranded DNA (dsDNA) was attached to classical solid silica-cored 
AuNSs through an Au–thiol bond. A small molecule (fluorescent molecule) bound 
reversibly to dsDNA. After NIR irradiation, SPR band of AuNS dehybridized the 
DNA lead to release of single strand DNA (ssDNA). The released ssDNA diffused 
into the nucleus of cell (Figure 8a).  
AuNSs composed of a mesoporous silica nanorattle core and a thin outer 
gold shell (SN@AuNSs) was also investigated. Docetaxel (DOC) as an anti-cancer 
drug and transferring (Tf) as a targeting moiety were incorporated into the 
SN@AuNSs, which exhibited cancer thermo-chemotherapy and imaging (Figure 
8b).  
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2) Gold nanorods (AuNRs) 
 
AuNRs usually have two LSPR peaks (transverse mode and longitudinal 
mode) from visible to NIR region [59]. To enhance drug contents of AuNRs, 
mesoporous silica-coated AuNRs (Au@SiO2
In addition, anti-cancer drug (doxorubicin, DOX) was intercalated into the 
DNA duplex strands which bound to the AuNRs surface, provide a DNA-targeting 
drug. After NIR laser illumination, DOX was released at the in vivo tumor site 
(Figure 8d). 
) was fabricated for hyperthermia 
therapy and imaging in cancer-cell (Figure 8c). 
 
3) Hollow gold nanospheres (HAuNSs) 
 
HAuNSs as the photothermal agnet was incorporated into the PLGA 
microsphere which containing paclitaxel (PTX) as an anti-cancer drug. Drug 
release was enhanced upon NIR laser illumination lead to inhibition of tumor in in 
vitro and in vivo systems (Figure 8e). Further thermo-chemotherapy of tumor was 
performed by targeting moiety-conjugated to DOX@HAuNSs (Figure 8f). 
 
4) Gold nanocages (AuNCs) 
 
AuNCs are hollow cubic gold nanostructures, which have ultrathin, porous 
walls, and truncated corners. The LSPR peaks of AuNCs can be adjusted by 
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controlling the wall thickness and the size of AuNCs. AuNC-based drug-delivery 
system was fabricated by coating the surface of AuNCs with thermosensitive 
polymers [poly-(N-isopropylacrylamide), pNIPAAm]. This pNIPAAm 
conformation was changed after temperature increase up to the certain threshold 
and the drug was release from the AuNC (Figure 8g). AuNC-based drug-delivery 
system combined magnetic targeting for cancer therapy was also studied (Figure 
8h). 
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Figure 8. Various kinds of Au plasmonic nanoparticles used for cancer 
photothermal therapy and optical imaging [52].  
(a) Thermal and NIR laser-triggered release of ssDNA from AuNSs. a) Schematic 
diagram of dsDNA-modified AuNSs. b) Scanning electron microscope (SEM) 
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image of the AuNSs. c) Extinction spectra of i) gold nanorods (AuNRs) and ii) 
AuNSs. 
(b) Docetaxel (DOC) as an anti-cancer drug and transferring (Tf) as a targeting 
moiety were incorporated into the SN (silica nanorattle)@AuNSs for the cancer 
thermo-chemotherapy and imaging. a) Schematic diagram of AuNSs with a core of 
silica nanorattle and with shells modified targeting ligand. b) Photo and infrared 
thermal image of tumor-bearing nude mouse after NIR light irradiation. c) 
Extinction spectrum of poly(ethylene glycol) (PEG)-modified gold nanoshells on 
silica nanorattles (pGSNs) and pGSNs-Tf, the inset is the TEM image of pGSNs-Tf. 
d) In vivo antitumor efficacy using pGSNs-Tf with NIR irradiation. 
(c) Au@SiO2 as a multifunctional theragnostic platform. a) The photothermal 
effect on lysosomal membrane integrity of A549 cells. b) Intracellular localization 
image of DOX (red) and Au@SiO2 (blue) in A549 cells stained with Lyso-Tracker 
(green) using two-photon confocal microscope. c) Controlled DOX release within 
A549 cells after NIR irradiation (live and dead cells were stained). 
(d) Targeted NIR-responsive AuNRs which are self-assembled with DNA for 
cancer thermo-chemotherapy. a) The schematic diagram of DNA assembled 
AuNRs. b) Antitumor effects of tumor-bearing mouse after different treatments. 
(e) HAuNS-loaded microspheres (HAuNS-MSs) for phtothermal-chemotherapy. a) 
Schematic diagram of PTX-HAuNS-MSs. b) Antitumor effects of U87 human 
gliomas grown in nude mice after different treatments. 
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(f) Targeted photothermal-chemotherapy of DOX-loaded HAuNSs. a) Schematic 
diagram of SH-PEG-c(TNYL-RAW) conjugated to HAuNSs. b) Antitumor effects 
of tumor-bearing mouse after different treatment. 
(g) AuNCs for controlled durg release with NIR laser irradiation. a) Schematic 
representation of polymer-coated AuNCs for drug delivery. b) Cell viability after 
different treatments. 
(h) Magnetic- and NIR- responsive drug release from AuNCs. a) Schematic 
diagram of Fe3O4
 
@CaP-capped AuNCs. b) Cell viabilities after different 
concentrations of AuNCs. 
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1.3. Motivation of drug-loaded Au plasmonic nanoparticles 
 
• Chemo-photothermal therapy and imaging of multidrug resistance in cancer 
 
The nanoparticles (NPs)-based photothermal treatment generates heat 
intracellularly, whereas conventional hyperthermia provides heat extracellularly. 
Thus, heat is delivered to cells more effectively with photothermal treatment than 
with hyperthermal treatment, and heat generated intracellularly is expected to 
facilitate the ability to overcome MDR tumors. A hypothesis is that, the 
intracellularly generated heat which is originated from NPs may enhance the 
uptake of doxorubicin (DOX) and suppress the export of DOX (Figure 9). To test 
this hypothesis, DOX-loaded-poly(lactic-co-glycolic acid)-Au half-shell 
nanoparticles (DOX-PLGA-Au H-S NPs) with targeting moieties (anti-DR4 
antibody) conjugated on the Au surface (DR4-DOX-PLGA-Au H-S NPs) were 
developed; DR4-DOX-PLGA-Au H-S NPs were NIR resonant due to the Au half 
shells. The in vitro and in vivo therapeutic effects of the chemo-photothermal 
treatment using these NPs and NIR irradiation were investigated. 
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Figure 9. Motivation of chemo-photothermal therapy and imaging of multidrug 
resistance in cancer using drug-loaded Au plasmonic nanoparticles. 
 
 
 
 
• Chemo-photothermal therapy and imaging of rheumatoid arthritis 
 
The nanoparticles (NPs)-based photothermal treatment have been mainly 
focused on cancer treatments [52]. However, a limited penetration depth of NIR 
light hinders their practical application in the cancer treatments.  
There are five motivations in therapy and imaging of rheumatoid arthritis; 1) 
Synovial inflammation in multiple joints within the penetration depth of NIR light 
(Figure 10), 2) Synovial proliferation of RA resembles solid tumors in many ways, 
including the leaky nature of the associated blood capillaries (similar w/ “enhanced 
permeability and retention (EPR) effect” in tumor) [60-61], 3) The NPs injected 
into the collagen induced arthritic (CIA) mice were effectively delivered to the 
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inflamed joint using RGD peptides (targeting moiety for inflammation), 4) The 
high retention of NPs (Fe-contained) at inflammation region under external 
magnetic field, 5) Adverse effects of drug (MTX) could be minimized by using 
carrier-NPs. 
 
 
 
 
 
Figure 10. Chemo-photothermal therapy of rheumatoid arthritis using drug-loaded 
Au plasmonic nanoparticles. 
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Chapter 2.  
In vivo chemo-photothermal therapy and imaging of 
multidrug resistance in cancer 
 
 
 
 
 
2.1. Introduction 
 
2.1.1. Multidrug resistance (MDR) in cancer 
 
Chemotherapy is one of the major approaches for treating cancer. Other 
major approaches include surgery, radiotherapy, hyperthermia, and immunotherapy. 
However, conventional cancer chemotherapy is limited by multidrug resistance 
(MDR) in at least 50% of patients [62-64]. As shown in Figure 11, cellular 
mechanisms of drug resistance have been deeply studied, and three different 
mechanisms were suggested [63].  
First, expression of ATP-dependent efflux pumps results in hydrophobic drug 
resistance (sometimes known as classical multidrug resistance). Intracellular drug 
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accumulation decreased because of efflux pumps expressed on cell surface. There 
are some kinds of drugs which are affected by efflux pumps, such as vinblastine, 
vincristine, doxorubicin, daunorubicin, and paclitaxel. Increased efflux pumps also 
related to decreased influx of drug into the cell. So, drugs that are entered via 
endocytosis did not work effectively. Examples drugs include methotrexate, 5-
fluorouracil, and cisplatin.  
Second, MDR is related to activation of detoxifying systems, such as DNA 
repair and the cytochrome P450 (a group of enzymes that are involved in drug 
metabolism and detoxification) mixed-function oxidases.  
Finally, MDR can result from blocked apoptosis pathways originated from 
malignant transformation of cancer, including cancer with mutant or non-functional 
p53 [65]. Alternatively, cells decrease ceramide levels or change cell-cycle 
machinery during exposure to chemotherapy, resulting in prevention of apoptosis 
of cancer. 
 
Figure 11. Cellular mechanisms of multidrug resistance (MDR) [63]. 
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One well-studied mechanism of MDR involves over-expression of 
membrane transporters, particularly ABC transporter P-glycoprotein (P-gp; known 
as MDR1, encodes by ABCB1) [66-68]. P-gp is a multidrug efflux pump which has 
twelve transmembrane regions and two ATP-binding sites (Figure 12). Stimulation 
of the ATPase activity of P-gp was performed after binding hydrophobic drugs to 
the transmembrane regions, leading to release of hydrophobic drugs to either outer 
of the membrane or the extracellular space and prevent intracellular accumulation 
[69].  
To overcome MDR, many MDR transporter inhibitors have been developed; 
some are in clinical trials, including verapamil (calcium channel blocker) and 
cyclosporin A (immunosuppressant) but none are currently in clinical use [63]. 
 
 
 
 
Figure 12. Structure and examples of ABC transporter P-glycoprotein (P-gp) [63]. 
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2.1.2. Naomaterials as therapeutic agents for MDR in cancer 
 
A variety of nanomaterials, including polymeric nanoparticles, lipid 
nanocapsules, micelles, and mesoporous silica particles that can carry 
chemotherapeutic agents, siRNA, photosensitizers, or a combination of multiple 
therapeutic agents have been developed. While these nanomaterials have been 
shown to reverse the actions of MDR transporters and altered apoptosis pathways 
to defeat MDR in cancer, clinical trials have been limited due to low efficacy 
and/or high toxicity [70]. To overcome these problems, combinatorial nanoparticles 
containing multiple cytotoxic drugs have been developed (Table 2) [70]. Among 
them, dual-drug liposomes (CPX-351 or CPX-1) with specific molar ratio of drugs 
showed superior therapy than traditional combination therapy and used for clinical 
trials (phase II). 
 
Table 2. Combination strategies of nanoparticle formulations against clinical cancer 
drug resistance [70]. 
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2.2. Experimental details 
 
2.2.1. Fabrication of DR4-DOX-PLGA-Au plasmonic NPs  
 
First, DOX-PLGA (Poly(lactic-co-glycolic acid) (PLGA; L:G molar 
ratio=50:50; MW=20,000)) NPs were synthesized using the solvent evaporation 
method [53-58]. Briefly, PLGA (200 mg) and DOX (6 mg) were dissolved in 
dichloroethane (20 ml), and this organic solution (oil phase) was added slowly 
drop-wise with distilled water (200 ml) containing Pluronic F-127 (200 mg) as a 
stabilizer under magnetic stirring. After mixing the oil and water phase, the mixture 
was emulsified by ultrasonication for 1 hr (400 W), followed by evaporation of 
organic solvent (dichloroethane) with stirring for 1 day. Then, the DOX-PLGA 
NPs were collected by centrifugation, and re-dispersed in 5 ml PBS by sonication. 
Next, the DOX-PLGA-Au H-S NPs were obtained by depositing 15-nm thick Au 
layers onto a monolayer of DOX-PLGA NPs, which were prepared by spin-casting 
aqueous suspensions of NPs on a silicon substrate. After depositing the Au film, 
DOX-PLGA-Au H-S NPs were released from the substrate into 1 wt% SH-PEG-
COOH solution by sonication and collected by centrifugation. For targeted delivery 
to DLD-1 or DLD-1/DOX cells over-expressing DR4 receptors, anti-DR4 
antibodies were conjugated on the surface of Au half-shells with protein G as a 
linker. To determine the amount of DOX loaded in NPs, 5 mg of dried NPs was 
dissolved in 1 ml of methylene chloride and the DOX extracted by adding 10 ml of 
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phosphate-buffered saline (PBS, pH 7.4). The amount of DOX was measured using 
an ultraviolet-visible spectrometer at 480 nm. 
 
2.2.2. Preparation and culture of DLD-1/DOX cells 
 
The DLD-1 colon cancer cell line was purchased from ATCC (American 
Type Culture Collection). DLD-1 cells were treated with DOX at the LD50 (50% 
lethal dose) for more than 4 months and established as the DOX-resistant DLD-1 
cell line (DLD-1/DOX).  
 
2.2.3. Human tumor xenografts  
 
Female BALB/c nude mice (8 weeks old, ~20 g) were supplied by Orient 
Bio INC. (Seongnam, Korea). All animal experiments were performed in 
accordance with the Korean Food and Drug Administration (KFDA) guidelines. 
Protocols were reviewed and approved by the Institutional Animal Care and Use 
Committee (IACUC) of the Yonsei Laboratory Animal Research Center (YLARC) 
(Permit #: 2011-0069). All mice were maintained in a specific pathogen-free 
facility at the YLARC. The animals had access to food and water ad libitum. For 
tumor induction, cells were harvested after trypsinization and 5 × 106 viable cells 
injected subcutaneously into the flanks of mice. Nude mice that underwent NIR 
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irradiation were anesthetized with Zoletil50/Rompum (v/v = 3) prior to NP 
injection. 
 
2.3. Results and discussion 
 
2.3.1. Characterization of DR4-DOX-PLGA-Au plasmonic NPs  
 
The DR4-DOX-PLGA-Au H-S NPs were prepared as shown in Figure 13a. 
The Au half-shell structure was clearly seen in the TEM image of these NPs 
(Figure 13b). The sizes and zeta-potentials of NPs in aqueous medium measured at 
25 °C by dynamic light scattering (DLS, Zetasizer Nano ZS, Malvern Instruments 
Ltd.) are summarized in Table 3. The average diameter of DR4-DOX-PLGA-Au 
H-S NPs was ~144 nm, and the SEM image of NPs revealed relatively uniform 
sizes (Figure 14a). The ultraviolet-visible/NIR absorption spectra of DOX-PLGA-
Au H-S and DR4-DOX-PLGA-Au H-S NPs exhibited a pronounced peak at 
approximately 820 nm due to Au half-shells (Figure 13c), suggesting that both 
nanoparticles can be used for photothermal treatment and in vivo NIR absorbance 
imaging.  
The DOX loading content (the ratio of DOX mass loaded into NPs relative 
to the total NP mass) was estimated to be ~3.9%. For targeted delivery to DLD-1 
or DLD-1/DOX cells that over-express DR4 receptors (Figure 15), anti-DR4 
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antibodies were conjugated on the Au surface and their conjugation confirmed by 
western blot for anti-DR4 antibody (Figure 14b). The ratio of the mass of anti-DR4 
antibody relative to the total mass of DR4-DOX-PLGA-Au H-S NPs was estimated 
to be ~4.8% based on the Bradford method using the Bio-Rad protein assay. I also 
tested the stability of NPs in serum by measuring the absorbance of the NP solution 
at 820 nm as a function of time (Figure 13d and Figure 14c). The absorbance was 
nearly unchanged within 24 h in 10% serum (Figure 13d), indicating that the NPs 
were stable in serum. 
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Figure 13. (a) Schematic diagrams showing the construction of DR4-DOX-PLGA-
Au H-S NPs. (b) TEM image of DR4-DOX-PLGA-Au H-S NPs. (c) Visible/NIR 
absorption spectra of DOX-PLGA NPs, PLGA-Au H-S NPs, DOX-PLGA-Au H-S 
NPs, and DR4-DOX-PLGA-Au H-S NPs. (d) Stability of DR4-DOX-PLGA-Au H-
S NPs. DR4-DOX-PLGA-Au H-S NPs were dispersed in 10% serum and their 
optical absorbance measured over a period of 24 h (red). Control PBS solution 
containing DR4-DOX-PLGA-Au H-S NPs (black).  
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Table 3. Characterization of prepared nanoparticles. 
Nanoparticles Size (nm) PDI a 
Zeta-potential b  (mV)c 
DOX-PLGA-Au H-S NPs 125 ± 2.529  0.143±0.029 -18.20±4.157 
Protein G-DOX-PLGA-Au H-S NPs 134 ± 3.117  0.209±0.015 -6.470±1.109 
DR4-Protein G-DOX-PLGA-Au H-S 
NPs 144 ± 3.394  0.206±0.019 -9.444±2.816 
DR4-Protein G-DOX-PLGA-Au H-S 
NPs  
(after NIR irradiation for 10 min) 
143 ± 2.040   0.181 ± 0.029  -9.444±2.816 
a,b,c
 
The size, polydispersiy index (PDI) and zeta-potential of the nanoparticles were 
measured by dynamic light scattering (DLS, Zetasizer Nano ZS, Malvern 
Instruments Ltd) at a concentration of approximately 1 mg of nanoparticles/1 ml of 
distilled water.  
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Figure 14. (a) SEM image of DR4-DOX-PLGA-Au H-S NPs. (b) Western blot for 
DR4 antibody in DR4-DOX-PLGA-Au H-S NPs. (c) Stability of DR4-DOX-
PLGA-Au H-S NPs in 10% serum. 
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Figure 15. Flow cytometry analysis of DR4 expression in DLD-1 and DLD-1/DOX 
cell lines (Red: isotype control, black: anti-DR4 Ab). 
 
 
To investigate the effects of NIR photothermal treatment combined with 
chemotherapy on DLD-1 and DLD-1/DOX cells, cell viability was measured using 
CCK-8 (Figure 16). DLD-1 and DLD-1/DOX cells (1 × 104
After treatment with DOX (100 µg/ml) for 3 days, cell viability was reduced 
to ~ 59% in DLD-1 cells and 90% in DLD-1/DOX cells. Next, DLD-1 or DLD-
1/DOX cells were pre-treated with PLGA-Au H-S NPs (30 µg/ml) containing no 
 cells/ml) were seeded 
onto 24-well plates and incubated in RPMI 1640 medium at 37 °C for 1 day. After 
each treatment, the cell viability, based on a CCK-8 assay, was determined by 
measuring the absorbance at 450 nm using a Multilabel Plate Reader (Victor X5, 
Perkin Elmer). All of the measurements were performed in triplicate. 
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DOX for 24 h and then exposed to NIR light (0.7 W/cm2) using a laser diode (λ = 
808 nm) for 10 min, followed by further incubation at 37 °C for 3 days. Upon NIR 
irradiation, the temperature increased to approximately 45 °C, which is comparable 
to the temperature of conventional hyperthermal treatments (Figure 17). In this 
case, the cell viability was reduced to ~ 80% for DLD-1 cells and ~ 68% for DLD-
1/DOX cells. Finally, DLD-1 or DLD-1/DOX cells were pre-treated with PLGA-
Au H-s NPs (30 µg/ml) for 24 h, and then treated with DOX (100 µg /ml) and 
exposed to NIR light (0.7 W/cm2
 
) for 10 min. Cell viability was reduced to 
approximately 18% and 41% for DLD-1 and DLD-1/DOX cells, respectively. 
These values were lower than expected for the additive effects of DOX and 
photothermal treatment on cell viability. These results suggest that MDR tumors 
may be defeated with this chemo-photothermal treatment. 
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Figure 16. Viability of DLD-1 and DLD-1/DOX cells with chemo-photothermal 
therapy. DLD-1 and DLD-1/DOX cells were treated with DOX only (DOX), NPs 
without (NPs) or with NIR (NPs + NIR irradiation), or NPs with NIR and DOX 
treatment (NPs + NIR irradiation + DOX). The additive therapeutic efficacies of 
chemo and photothermal treatments were estimated using the relationship Tadditive = 
100 – (fchemo × fphotothermal) × 100, where f is the fraction of surviving cells after each 
treatment. Data represent mean ± SD (n = 3). When the chemo-photothermal 
therapy is compared to photothermal therapy and the additive value using the t test, 
p-value ≤ 0.005 (*p = 0.003, **p = 0.0017). 
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Figure 17. The schematic diagram of a 24 well plate containing cells under NIR 
irradiation of 0.7 W/cm2
 
 for 10 min (top) and its thermal image (bottom). 
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2.3.2. DOX uptake in DLD-1/DOX cells  
 
To investigate the origin of the synergistic effects of chemo-photothermal 
treatment on DLD-1 and DLD-1/DOX cells, the influence of photothermal 
treatment on DOX uptake in DLD-1 and DLD-1/DOX cells was investigated. 
Human colon cancer (DLD-1) and DOX-resistant DLD-1 (DLD-1/DOX) cell lines 
were treated with a DOX solution (20 µg/ml), and fluorescence images were 
acquired before and after incubation at 45 °C. For the photothermal treatments, 
DLD-1 and DLD-1/DOX cells were first incubated with PLGA-Au H-S NPs (30 
µg/ml, without DOX) for 24 h. The cells were then treated with DOX and exposed 
to NIR light delivered at 0.7 W/cm2 by a laser diode (λ = 808 nm) for 10 min. The 
cellular uptake of DOX was also measured by a flow cytometry (BD Biosciences). 
As a control, DLD-1 and DLD-1/DOX cells were treated with DOX (20 µg/ml) at 
37 °C for 4 h, followed by the measurement of intracellular DOX retention with 
flow cytometry after incubating for 1, 2, 3, and 6 h. To test the photothermal 
treatment, DLD-1 or DLD-1/DOX cells were treated with DOX (20 µg/ml) in the 
presence of PLGA-Au H-S NPs (30 µg/ml, without DOX) for 4 h, exposed to NIR 
light (0.7 W/cm2) for 10 min, and washed with PBS. Uptake was measured in 
DOX-treated DLD-1 and DLD-1/DOX cells exposed or not exposed to NIR light. 
Approximately 10,000 events were acquired per sample, and the data were 
analyzed using FACS CompTM software. Forward and side light scatter gates were 
set to exclude dead cells, debris, and cell aggregates. 
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As a control, DLD-1 and DLD-1/DOX cells were incubated at 37 °C and 
treated with 20 µg/ml DOX solution, suboptimal dose of one-fifth of LD50. At 
37°C, red fluorescence was observed in DLD-1 cells due to internalized DOX 
(Figure 18a). In contrast, red fluorescence was not detected in DLD-1/DOX cells at 
37 °C (Figure 18b), indicating that the DLD-1/DOX cells were pumping DOX out 
of the cells. 
For photothermal treatments, DLD-1 and DLD-1/DOX cells were incubated 
with PLGA-Au H-S NPs (30 µg/ml, without DOX) for 24 h. Next, the cells were 
treated with 20 µg/ml DOX solution and exposed to NIR light (0.7 W/cm2
 
) for 10 
min. Unlike incubation at 37°C, the photothermal treatment resulted in enhanced 
uptake of DOX in both DLD-1 and DLD-1/DOX cells (Figure 18c and d). These 
results suggest that the internalized DOX was not immediately pumped out from 
the DLD-1/DOX cells after the photothermal treatment, which led to increased 
intracellular accumulation of DOX. For a comparison, the effects of hyperthermal 
treatments by warming cancer cells to 45 °C for 10 min, which was the same 
temperature increase caused by NIR irradiation were also investigated. Compared 
to the control, no significant change in DOX accumulation was observed at 45 °C 
for the two cell types (Figure 18e and f). 
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Figure 18. Thermal and photothermal effects on DOX uptake in a multidrug-
resistant cancer cell line. Fluorescence images show DOX retention in cancer cells 
sensitive (DLD-1) or resistant (DLD-1/DOX) to DOX. Thermal effects are shown 
in cells treated with 20 µg/ml of DOX and incubated at 37 °C (a and b) or 45 °C 
for 10 min (e and f). Photothermal effects are shown in cells pre-treated with 
PLGA-Au H-S NPs for 24 h followed by 20 µg/ml DOX, and exposed to NIR light 
(0.7 W/cm2
Scale bar = 50 µm. (red : DOX, blue : cell nucleus). 
, 10 min) (c and d). NIR irradiation elevated the temperature to 45 °C. 
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To quantify the accumulation of drug in DLD-1 and DLD-1/DOX cells after 
the photothermal treatment, flow cytometric analysis of DOX fluorescence in 
DLD-1 and DLD-1/DOX cells exposed to NIR light was performed. For the 
control, DLD-1 and DLD-1/DOX cells were treated with DOX (20 µg/ml) at 37 °C 
for 4 h and intracellular DOX retention measured by flow cytometry 1, 2, 3, and 6 
h later. We found that DOX was absorbed well in DLD-1 cells but then actively 
pumped out to maintain baseline intracellular levels after 6 h. To test the 
photothermal treatment, DLD-1 or DLD-1/DOX cells were treated with DOX (20 
µg/ml) in the presence of PLGA-Au H-S NPs (30 µg/ml) for 4 h and then exposed 
to NIR light (0.7 W/cm2
 
) for 10 min, followed by washing with PBS. An increased 
fluorescence intensities for both DLD-1 and DLD-1/DOX cells exposed to NIR 
light were observed (Figure 19). These observations support the accumulation of 
DOX in DLD-1/DOX cells being enhanced by photothermally generated heat.  
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Figure 19. Thermal and photothermal effects on DOX retention in a multidrug 
resistance cancer cell line. (a) Flow cytometric analysis of DOX-treated DLD-1 
and (b) DLD-1/DOX cells. 
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2.3.3. P-gp expression and activity in cells after photothermal treatment  
 
The efflux of DOX is related to the level of P-gp expression [71-72]. 
Therefore, P-gp expression in DLD-1/DOX cells with or without photothermal 
treatment was measured. P-gp expression level was measured by a flow cytometry 
(BD Biosciences). Briefly, DLD-1 and DLD-1/DOX cells were incubated with 
PLGA-Au H-S NPs in complete RPMI 1640 medium at 37 °C for 24 h. After each 
treatment, the cells were blocked by 2% BSA in PBS at 4 °C for 30 min, followed 
by diluted anti-P-gp antibody (BD) in PBS with 1% BSA at 4 °C for 1 h. Cells 
were washed twice with PBS and incubated with Alexa 488-congugated IgG in 
PBS with 1% BSA. Approximately 10,000 events were acquired per sample and 
the data analyzed using FACS CompTM
Regardless of whether cells underwent photothermal treatment, P-gp 
expression did not change (Figure 20). However, Figure 18 and Figure 19 show 
that DOX efflux was suppressed in photothermally treated DLD-1/DOX cells.  
 software (BD). Forward and side light 
scatter gates were set to exclude dead cells, debris, and cell aggregates. 
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Figure 20. P-glycoprotein expression measured by flow cytometry for DLD-1 and 
DLD-1/DOX cells after treatment with NIR irradiation or incubation at 45 °C. 
 
 
Based on these results, I conjectured that intracellularly-generated heat may 
reduce the activity of P-gp without changing protein levels. To test this idea, both 
DLD-1 and DLD-1/DOX cells were treated with PLGA-Au H-S NPs (30 µg/ml) 
and NIR, followed by the measurement of ATPase activity. P-gp is an ATP-
binding cassette (ABC) transporter. In the ATPase assay, inorganic phosphate 
generated by ATP hydrolysis, which is linked with transporters, was determined by 
colorimetry as described previously [73]. After NIR irradiation, the ATPase 
activity of DLD-1 and DLD-1/DOX cells was measured using the Quantichrom 
ATPase/GTPase assay kit (Bioassay Systems) according to the manufacturer’s 
instructions. 
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As shown in Figure 21, photothermal treatment with NIR decreased the 
ATPase activity. In contrast, warming the cells by incubation at 45 °C for 10 min 
resulted in no change in ATPase activity.  
 
 
 
Figure 21. ATPase activities of DLD-1/DOX cells after treatment with NIR 
irradiation or incubation at 45 °C. 
 
 
The fluorescence images of DLD-1 and DLD-1/DOX cells treated with DOX, 
NPs, and NIR are shown in Figure 22. Fluorescence intensity increased in DLD-
1/DOX cells at 1 h, and then significantly decreased at 2 h, after NIR irradiation. 
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These results suggest that NIR irradiation enhanced the intracellular accumulation 
of DOX in DLD-1/DOX cells by NIR; however, the DOX retention time was short, 
so DOX was cleared out at 2 h. Next, we exposed DLD-1/DOX cells to NIR light 
again at 3 h. Interestingly, the fluorescence intensity increased again, indicating 
that intracellular accumulation of DOX was enhanced. These results support our 
idea that P-gp activity is affected by NP-based photothermal treatment. 
 
 
 
Figure 22. Fluorescence images of DLD-1 and DLD-1/DOX cells after different 
treatments. After one or twice exposures to NIR, the cells were washed with PBS 
and incubated in DOX-free media for the indicated times. Scale bar = 50 µm.  
(red : DOX, blue : cell nucleus). 
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To confirm the uptake of NPs into cells, TEM study was also performed. 
DLD-1 and DLD-1/DOX cells (5 × 105
TEM images of NP-treated DLD-1/DOX cells are presented in Figure 23. 
Before NIR irradiation, DLD-1/DOX cells incubated with PLGA-Au H-S NPs (30 
µg/ml, without DOX) at 37 °C for 24 h had internalized NPs by endocytosis, and 
the NPs were located primarily inside vesicles (Figure 23a) . After NIR irradiation 
for 10 min, apparent morphological changes were not noted and the NPs were 
observed inside vesicles (Figure 23b and c).  
 cells/ml) seeded onto 6-well plates were 
incubated with PLGA-Au H-S NPs (30 µg/ml, without DOX) in 3 ml RPMI 1640 
medium at 37 °C for 24 h. The NP-treated cells were rinsed three times with PBS, 
dissociated using trypsin-EDTA, centrifuged, and the cell pellet collected. Ultra-
thin (80 nm) sections of the cell pellet were prepared using a standard method and 
examined by TEM (JEM-1011, JEOL, Japan). 
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Figure 23. (a) TEM images of DLD-1/DOX cells incubated for 24 h with PLGA-
Au H-S NPs at 37 °C. (b, c) TEM images of DLD-1/DOX cells incubated with 
PLGA-Au H-S NPs and then exposed to NIR light (0.7 W/cm2 for 10 min). The 
TEM images were taken at 1 h (b) and 6 h (c) after NIR irradiation. 
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Figure 24 shows the optical image and fluorescence image of DLD-1/DOX 
cells incubated with DOX-PLGA-Au H-S NPs (30 µg/ml, DOX loaded in PLGA) 
obtained 6 h after NIR irradiation and PBS washing. Internalized NPs were still 
observed in DLD-1/DOX cells. As almost all DOX was pumped out at 6 h from the 
cells treated with DOX solution (Figure 14), these results imply that the NPs were 
much more slowly pumped out from DLD-1/DOX cells compared to DOX solution.  
 
 
 
Figure 24. Optical image and fluorescence image of DOX-PLGA-Au H-S NPs 
(DOX loaded in PLGA) in DLD-1/DOX cells 6 h after NIR irradiation (0.7 W/cm2
 
, 
10 min). (red : DOX which is loaded in PLGA-Au H-S NPs, blue : cell nucleus). 
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2.3.4. In vivo targeting efficacy  
 
To evaluate the in vivo targeting efficacy of NPs, DR4-DOX-PLGA-Au H-S 
NP solution (200 µl of 1 mg/ml mixture dispersed in PBS) was intravenously 
injected into the tail vein of DLD-1 or DLD-1/DOX tumor-bearing mice. The 
injected DR4-DOX-PLGA-Au H-S NPs were monitored 24 h after injection by 
acquiring in vivo NIR absorbance images using the eXplore Optix System 
(Advanced Research Technologies Inc., Montreal, Canada). The mice were 
anesthetized with Zoletil50/Rompum (v/v = 3) during acquiring images. 
Increased absorbance intensity was observed in the tumor regions in both 
DLD-1 and DLD-1/DOX tumor-bearing mice, indicating that DR4-PLGA-Au H-S 
NPs were effectively delivered to the tumor site, where they accumulated (Figure 
25). 
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Figure 25. In vivo NIR absorbance images of (a) DLD-1 and (b) DLD-1/DOX 
tumor-bearing mice measured 24 h after intravenous injection of DR4-PLGA-Au 
H-S NP solution. The dotted circle is the tumor-containing region. 
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To determine whether drug efflux could also be suppressed by photothermal 
treatment in MDR tumor-bearing mice, I used technetium-99m 
methoxyisobutylisonitrile (99mTc-MIBI), a lipophilic cationic radiopharmaceutical 
transport substance that, like DOX, can be pumped out by P-gp, thus, it is often 
used for imaging MDR tumors [74]. 99mTc-methoxisobutylisonitrile (99mTc-MIBI) 
was prepared using the Mallinckrodt® kit (Mallinckrodt Medical, Petten, the 
Netherlands) according to the manufacturer’s instructions. The radiochemical 
purity was greater than 95%. DLD-1/DOX tumor-bearing mice were anesthetized 
with Zoletil50/Rompum (v/v = 3) and 18.5 MBq of 99mTc-MIBI injected 
intravenously. Early and delayed 99m
I acquired 
Tc-MIBI images were acquired at 10 min, 3 h, 
and 4 h after injection of the radiotracer. Images were acquired for 10 min using a 
single head ARGUS gamma camera (Philips Medical Systems, Cleveland, OH, 
USA) with a matrix size of 512 × 512 × 16 with a pinhole collimator. 
99mTc-MIBI in DLD-1/DOX mice carrying tumors on both the left 
and right flank. The DR4-DOX-PLGA-Au H-S NP solution (200 µl) was injected 
intravenously. Twenty-four hours after injection, only the right tumor was 
irradiated with NIR light (1.82 W/cm2
 
) for 10 min. The temperature of the exposed 
tumor increased to approximately 45 °C, but the region that was not exposed to 
NIR light was 36.5 °C (Figure 26).  
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Figure 26. Thermal images of the (a) DLD-1 and (b) DLD-1/DOX tumor-bearing 
mice. DR4-PLGA Au H-S NPs solution was intravenously injected into the mice 
and NIR light of 1.82 W/cm2
 
 was irradiated only to the tumor region with a 
diameter of ~ 0.9 cm for 10 min. 
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As shown in Figure 27, almost no uptake was detected in either the left or 
right tumor 10 min after NIR irradiation. However, at 180 and 240 min, 99mTc 
MIBI uptake was increased in only the right tumor, which had been exposed to 
NIR light; in contrast, the intensity of 99mTc-MIBI was nearly unchanged for the 
non-irradiated, left tumor. Consequently, the ratios of 99mTc-MIBI accumulation in 
the right and left tumors were approximately 1.0, 2.5 and 3.0 at 10, 180 and 240 
min, respectively. These 99m
 
Tc-MIBI images suggest that the NIR photothermal 
treatment inhibited P-gp activity, which suppressed drug efflux and enhanced drug 
accumulation.  
 
 
Figure 27. 99mTc-MIBI scintigraphy imaged at different times for an NP-treated 
DLD-1/DOX tumor-bearing mouse with tumors on both the left and right thighs. 
Only the right tumor (arrow) was irradiated with NIR light of 1.82 W/cm2 for 10 
min just before 99mTc-MIBI injection, and images were taken 10, 180, and 240 min 
after NIR irradiation. 
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2.3.5. In vivo therapeutic effects 
 
To assess the therapeutic efficacy of targeted chemo-photothermal treatment 
on MDR tumors, treatments in DLD-1/DOX tumor-bearing mice and DLD-1 
tumor-bearing mice were compared (Figure 28). Both groups of mice were divided 
into five test groups (n = 3 mice per group) that received saline (control) or DOX 
with or without NPs, and with or without NIR exposure (Table 4). When tumors 
developed to approximately 100 mm3 in diameter, treatment was administered via 
intravenous tail injection (200 µl). The tumor volumes were measured in each 
group and plotted as a function of time, with the relative tumor volume (%) defined 
as (V-V0)×100/V0, where V0
DOX chemotherapy was delivered intravenously using either 10 mg/kg DOX 
solution or a 0.18 mg/kg solution of DOX inside DR4-DOX-PLGA-Au H-S NPs. 
In DLD-1 tumor-bearing mice, 10 mg/kg DOX significantly reduced the tumor 
volume compared to saline controls (Figure 28a). In contrast, the tumor volume 
increased more rapidly with DR4-DOX-PLGA-Au H-S NPs without NIR exposure 
than with DOX treatment alone. This difference was attributed to a slow release of 
DOX from PLGA NPs and the low concentration of DOX inside the NPs. On the 
other hand, when mice were treated with empty DR4-PLGA-Au H-S NPs 
(containing no DOX) and exposed to NIR light, the tumor growth was reduced to a 
rate similar to that of the group treated with the high-dose DOX solution. Finally, 
when DLD-1 tumor-bearing mice were treated with DR4-DOX-PLGA-Au H-S 
 was the initial tumor volume. 
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NPs (0.18 mg/kg DOX) and NIR light, the tumor volume increased much more 
slowly than in the DOX injection group (Figure 28), demonstrating a synergistic 
effect of DOX combined with NIR exposure. 
In DLD-1/DOX tumor-bearing mice, the tumor growth rate after DOX 
injection was similar to that of the saline injection, as expected, due to the drug 
resistance of DLD-1/DOX cells. However, when these mice were treated with 
DR4-DOX-PLGA-Au H-S NPs and exposed to NIR light, the tumor growth rate 
was considerably slower than that of DOX-treated mice (Figure 28b). This finding 
was in agreement with the in vitro cell viability test (Figure 16).  
In fact, in DLD-1/DOX tumor-bearing mice (saline control), the tumor 
volume increased more slowly than in DLD-1 tumor-bearing mice (saline control). 
Therefore, I normalized the change in tumor volume with respect to the change 
observed in the control group (∆V/∆Vcontrol), and the relative change was plotted as 
a function of time (Figure 29). When DLD-1/DOX tumor-bearing mice were 
treated with DR4-DOX-PLGA-Au H-S NPs and exposed to NIR light (1.82 W/cm2) 
for 10 min at 24 h after NP injection, ∆V/∆Vcontrol was much smaller than that of the 
groups treated with DOX only or DR4-PLGA-Au H-S NPs and NIR irradiation 
These findings suggest that the growth of DLD-1/DOX tumor cells was inhibited 
by targeted chemo-photothermal treatment, which was attributed to the prolonged 
retention of DOX in DLD-1/DOX cells. Moreover, the DR4-DOX-PLGA-Au H-S 
NPs used in the chemo-photothermal treatment contained only 0.18 mg/kg, which 
corresponds to 1.8% of the concentration used in DOX treatment; alone this low 
DOX treatment did not affect tumor growth rates, which were similar to those of 
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control-treated DLD-1/DOX tumor-bearing mice. These results suggest that the 
targeted chemo-photothermal treatment kills MDR tumors with minimal side 
effects. 
 
 
Table 4. Summary of treatments in the therapeutic efficacy of MDR in cancer. 
Group Treatment DOX (mg/kg) a NIR light (W/cm2)b 
1 Saline - - 
 2 DOX solution 10 - 
3 DR4-DOX-PLGA Au H-S NPs 0.18 - 
4 DR4-PLGA Au H-S NPs - 1.82 
5 DR4-DOX-PLGA Au H-S NPs 0.18 1.82 
 
aAdministrated content was injected intravenously by tail vein in a volume 200 μl 
with a nanoparticle concentration of 1 mg/ml. bThe tumor was exposed to NIR light 
(1.82 W/cm2
 
) for 10 min with a laser diode (λ = 808 nm) at 24 h post-injection. 
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Figure 28. Relative change in tumor volume over time in (A) DLD-1 and (B) DLD-
1/DOX tumor-bearing mice treated with saline (■), DOX solution ( ●), DR4-DOX-
PLGA-Au H-S NPs (▲), DR4-PLGA-Au H-S NPs and NIR exposure (▼), or 
DR4-DOX-PLGA-Au H-S NPs and NIR exposure (◀). The tumor growth rate (%) 
was (V-V0) × 100/V0, where V0 is the initial tumor volume. Data represent mean ± 
SD (n = 3).  
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Figure 29. ∆V/∆V0 versus time for DLD-1 and DLD-1/DOX tumor-bearing mice 
treated differently. DOX solution (●), DR4-DOX-PLGA Au H-S NPs (▲). DR4-
PLGA Au H-S NPs and NIR exposure (▼), or DR4-DOX-PLGA Au H-S NPs and 
NIR exposure (◀). ∆V0
 
 is the tumor volume change of the control group. 
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2.3.6. In vivo toxicity  
 
DR4-DOX-PLGA Au H-S NPs were designed to target DR4-expressing cells. 
I histologically examined major organs from DLD-1/DOX tumor-bearing mice to 
determine whether any morphological changes occurred due to toxicity. The organs 
were collected 28 days after chemo-photothermal treatment. Tissues were fixed in 
10 % buffered formalin-saline at 4 o
No apparent tissue damage was observed as shown in Figure 30. I also 
measured body weight during the treatments (Figure 31). The DLD-1/DOX tumor-
bearing mice treated with DOX solution lost weight over 28 days. However, the 
DLD-1/DOX tumor-bearing mice that received chemo-photothermal treatment did 
not exhibit weight loss. These results indicate that the targeted chemo-photothermal 
treatment did not result in significant toxicity. 
C overnight. Then, tissues were embedded in 
paraffin blocks. Paraffin sections (5 µm thick) were mounted on glass slides for 
hematoxylin and eosin (H&E) staining.  
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Figure 30. Histology of major organs (heart, kidney, liver, lung and spleen) 
obtained from DLD-1/DOX tumor-bearing mice. The tissues were collected at 28 
days after intravenous injection of saline (upper panel) or DR4-DOX-PLGA-Au H-
S NPs (lower panel) followed by NIR irradiation. 
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Figure 31. Relative body weight change versus time for DLD-1/DOX tumor-
bearing mice treated with saline (■), DOX solution (●), DR4-DOX-PLGA Au H-S 
NPs (▲). DR4-PLGA Au H-S NPs and NIR exposure (▼), or DR4-DOX-PLGA 
Au H-S NPs and NIR exposure (◀).  
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2.4. Summary 
 
I investigated the therapeutic effects of a targeted chemo-photothermal 
treatment with DR4-DOX-PLGA-Au H-S NPs and NIR irradiation in a DOX-
resistant DLD-1 (DLD-1/DOX) cell line and DLD-1/DOX tumor-bearing mouse 
model. The targeted chemo-photothermal treatment decreased the tumor growth 
rate in the presence of even a small amount of DOX in DLD-1/DOX tumor bearing 
mice, likely due to the photothermally generated heat, reducing drug efflux from 
DLD-1/DOX cells and increasing intracellular drug accumulation.  
The decrease in P-gp activity might be attributed to the decrease in ATPase 
activity caused by intracellularly-generated heat, although further studies are 
necessary to investigate how the chemo-photothermal treatment influences 
the activity of P-gp. These results demonstrate that this targeted chemo-
photothermal treatment can achieve high therapeutic efficacy against MDR tumors 
with low toxicity. 
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Chapter 3.  
In vivo chemo-photothermal therapy and imaging of 
rheumatoid arthritis 
 
 
 
 
 
3.1. Introduction 
 
3.1.1. Rheumatoid arthritis (RA) 
 
Rheumatoid arthritis (RA) is progressive and disabling autoimmune disease 
which is characterized by bony erosion and synovial hyperplasia that affects the 
small diarthrodial joints of the hands and feet, leading to disability [75-78]. Three 
phases of progression of RA were known as; 1) initiation phase, due to non-
specific inflammation, 2) amplification phase, owing to T cell activation, 3) 
chronic inflammatory phase with tissue injury, induced by cytokines, such as 
interleukin-1 (IL-1), interleukin-6 (IL-6), and tumor-necrosis factor (TNF)-α. In 
addition to an inflammation in the synovium, B cells, CD4+ T cells, and 
macrophages infiltrate the synovium. Also, significant increase in fibroblast-like 
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and macrophage-like synoviocytes results in hyperplasia of the intimal lining. 
Degradative enzymes, such as serine proteases, aggrecanases, and 
metalloproteinases digest the extracellular matrix and eventually destroy the 
articular structures (Figure 32). RA incidence of the adult population worldwide is 
0.5 ~ 1.0%.  
 
 
Figure 32. Illustration of progression in rheumatoid arthritis. 
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The cause of RA was not completely understood but cytokine networks were 
known as relation with pathogenesis of RA [76]. New molecular techniques were 
developed by the late 1980s, and cytokines in RA synovium and synovial fluid 
were measured. Rheumatoid synovium produces fibroblast and macrophage 
cytokines, such as TNF-α, IL-1, IL-6, IL-15, IL-18, granulocyte–macrophage 
colony-stimulating factor (GM-CSF), various chemokines, and many others. The 
role of cytokine networks in RA is that fibroblasts and macrophages produce 
cytokines each other to initiate RA (Figure 33). To treat RA, biological agents, such 
as anti-TNF-α antibody, were used to interrupt cytokine networks. The anti-TNF-α 
antibody can slow or prevent the progression of cartilage damage of RA owing to 
suppression of osteoclasts in joint [79].  
 
 
 
Figure 33. Cytokine networks in rheumatoid arthritis [76]. Proinflammatory 
cytokines (+) and anti-inflammatory proteins (–) are indicated. 
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A RANKL, the RANK (receptor activator of nuclear factor (NF)-κB) ligand, 
which is expressed by T cells and synoviocytes is most importantly related to bone 
erosions in RA [76]. The role of RANKL in RA has been studied in in vivo systems. 
For example, the RANKL which is activated by T cells, increase osteoclasts and 
deteriorate bone loss in rat adjuvant arthritis [80]. High levels of osteoprotegerin 
(OPG) and soluble-RANKL in RA are decreased after treatment of TNF inhibitors 
[81]. Moreover, bone erosion was diminished in RANKL-knockout mice [82]. 
Understanding the mechanisms of cytokine gene expression is important to 
treatment of RA. The RANKL regulates genes which contribute to inflammation in 
RA. These genes encompass IL-6, IL-8, TNF-α, cyclooxygenase-2 (COX-2), and 
inducible nitric oxidase synthase (iNOS). A mitogen-activated protein (MAP) 
kinases are also important regulators of cytokine and could be targeted in RA. 
These kinases, including p38 mitogen-activated protein kinase, extracellular signal-
regulated kinase (ERK), and c-Jun N-terminal kinase (JNK) are expressed in 
synovial tissue of RA [83]. Pre-clinical studies have shown that inhibitor of p38 
mitogen-activated protein kinase was used as therapeutic agents of RA in animal 
model [84].  
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3.1.2. Disease-modifying anti-rheumatic drugs (DMARDs) 
 
Disease-modifying anti-rheumatic drugs (DMARDs) are the main strategy 
for the treatment of RA, and methotrexate (MTX) is the most widely used 
DMARD for the treatment of RA (Figure 34) [85]. MTX has a structural analogue 
of folic acid which can competitively inhibit the binding of dihydrofolic acid to the 
enzyme dihydrofolate reductase, eventually inhibits DNA formation and cell 
proliferation. MTX can be prescribed alone or with other DMARDs or biologic 
agents for combination therapy. However, despite its good therapeutic efficacy, the 
long-term administration of MTX may induce serious systemic complications, 
including infection, hepatitis, and bone marrow suppression [86-87].  
 
 
 
Figure 34. Chemical structure of methotrexate (MTX). 
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From a clinical point of view, increasing the dose of MTX in RA patients, 
who have several refractory joints or MTX dose-related side effects, or continuiting 
MTX in patients who have systemic disease, such as interstitial lung disease, viral 
hepatitis, or bone marrow dysfunction, may provoke more unwanted adverse 
effects. Therefore, the novel delivery systems to maintain a high concentration of 
MTX within the joint spaces, which is the main area of inflammation, by 
administration of small dosage of drugs and to reduce side effects in accordance 
with systemic administration of MTX would be an attractive and effective tool for 
RA treatment.  
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3.2. Experimental details 
 
3.2.1. Fabrication of RGD-MTX Au plasmonic NPs and MTX-Au/Fe/Au 
plasmonic NPs 
 
MTX-PLGA (Poly(lactic-co-glycolic acid) (PLGA; L:G molar ratio=50:50; 
MW=20,000)) NPs were synthesized using the solvent evaporation method [53-58]. 
Briefly, PLGA (200 mg) and MTX (6 mg) were dissolved in dichloroethane (20 
ml), and this organic solution (oil phase) was added slowly drop-wise with distilled 
water (200 ml) containing Pluronic F-127 (200 mg) as a stabilizer under magnetic 
stirring. After mixing the oil and water phase, the mixture was emulsified by 
ultrasonication for 1 hr (400 W), followed by evaporation of organic solvent 
(dichloroethane) with stirring for 1 day. Then, the MTX-PLGA NPs were collected 
by centrifugation, and re-dispersed in 5 ml PBS by sonication. After that, 15-nm-
thick Au film was deposited onto an MTX-PLGA nanoparticle monolayer prepared 
on a Si substrate using a thermal evaporator. After depositing the Au film, Au-
deposited MTX-PLGA nanoparticles were released into 1 wt% SH-PEG-COOH 
solution from the substrate by sonication and collected by centrifugation. The 
collected carboxylic acid-terminated MTX-PLGA-Au nanoparticles (74.6 μM) and 
EDC (746.7 μM) were dissolved in 25 ml of 0.2 M phosphate buffer (pH 6.0) and 
stirred at room temperature. After 30 min, cyclic RGD (74.6 μM) in 3 ml of 
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distilled water was added and the pH value of the reaction mixture adjusted to 8.0 
by adding 0.5 M NaOH. The reaction mixture was then left at room temperature for 
the RGD peptides to bind covalently to the COOH group of the SH-PEG-COOH 
chains immobilized on the surface of the Au half-shells. After 12 h, RGD-MTX-
PLGA-Au nanoparticles were collected by centrifugation for 30 min at 100,000 
rpm; the supernatant containing un-reacted cyclic RGD was discarded. The 
resulting RGD-MTX-PLGA-Au nanoparticles were characterized using an 1H-
NMR spectrometer (300 MHz, DMSO-d6, 25 oC, TMS, Varian Gemini-300 
spectrometer) with δ values of 8.1 ~ 8.6 (-NH(NH2)=NH of cyclic RGD), 5.2 (m, 
CH of PLGA), 3.6 (s, CH2 of PEG), and 1.5 (d, CH3
In the case of MTX-Au/Fe/Au plasmonic NPs, the electron-beam evaporator 
was used to deposit the films of 10-nm-thick Au/ 5-nm-thick Fe/ 10-nm-thick Au 
onto MTX-PLGA NPs monolayer, which was prepared by spin-coating aqueous 
suspension of MTX-PLGA NPs on a Si substrate. The Si substrate was immersed 
in SH-PEG-COOH (1 wt%) solution followed by sonication. After that, the 
COOH-terminated MTX-Au/Fe/Au plasmonic NPs were obtained by 
centrifugation. For targeted delivery to the inflammation region, the cyRGD 
peptides (3 mg) were conjugated on the outer Au half-shell surface of MTX-
Au/Fe/Au plasmonic NPs with conventional EDC (4 mg) /NHS (4 mg) coupling 
reaction in 9 ml of PBS at 4 °C for 1 day. After the reaction, MTX-Au/Fe/Au 
plasmonic NPs were collected by centrifugation, and were re-dispersed in 1.5 ml of 
PBS. These cyRGD peptides conjugated on MTX-Au/Fe/Au plasmonic NPs were 
analyzed using a 
 of PLGA).  
1H-NMR spectrometer (Varian Gemini-300, DMSO-d6) with 
- 79 - 
 
characteristic δ values of 1.5 (d, -CH3 of PLGA), 3.6 (s, -CH2- of PEG), 5.2 (m, 
≡CH of PLGA), 8.1 - 8.6 (-NH(NH2)=NH of cyRGD). In the FT-IR spectrum 
(Bruker Vertex 70), there were characteristic peaks at 1,700 cm-1 (C=O stretch), 
3,480 cm-1 (-N-H stretch), and 1,650 cm-1 (-N-H bend). The cyRGD peptides 
contents in the MTX-Au/Fe/Au plasmonic NPs were quantified by high pressure 
liquid chromatography (HPLC) using a C18 column (water Noca-Pak C18
Schematic diagram of fabrication of RGD-MTX Au plasmonic NPs and 
MTX-Au/Fe/Au plasmonic NPs was shown in Figure 35. 
, 3.9 × 
300 mm, 4 μm).  
 
 
 
Figure 35. Preparation of RGD-MTX Au plasmonic NPs (upper panel) and MTX-
Au/Fe/Au plasmonic NPs (lower panel). 
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3.2.2. Preparation and culture of fibroblast-like synoviocyte (FLS) cells 
 
Synovial tissues were obtained from 3 patients with RA who underwent knee 
joint replacement surgery at Severance Hospital, Yonsei University College of 
Medicine, Seoul, Korea. All patients satisfied the 1987 revised American College 
of Rheumatology (ACR) classification criteria for rheumatoid arthritis. FLS cells 
were isolated and cultured as described previously [88]. Cells obtained from 
passages at 4 to 8 were used in these experiments. FLSs were seeded into 12-well 
plates at a density of 1.5 × 105 
To quantify the apoptotic cells of cultured FLS, fluorescein isothiocyanate 
(FITC) Annexin V Apoptosis Detection kit (BD biosciences, San Diego, CA) was 
used according to the manufacturer’s protocol. Cells were treated with MTX (30 
μM), MTX (0.13 μM, NPs dose), and MTX-PLGA Au plasmonic NPs with NIR 
irradiation and incubated at 37
cells/well in Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with 10% fetal bovine serum (FBS; GibcoBRL, 
GrandIsland, NY), 2mM ʟ-glutamine, 100 units/ml of penicillin, and 100 g/ml of 
streptomycin. TNF-α (10 ng/ml) was used to induce inflammation in FLS cells. 
FLS cells were incubated at 37 °C.  
 °C for 48 and 72 h. NIR irradiation was done 24 h 
after treatment with the power of 0.73 W/cm2 for 10 minutes. After NIR irradiation, 
the temperature increases up to 42 °C. Treated cells were harvested by 
centrifugation, and washed in cold PBS. Annexin V-FITC and propidium iodide 
(PI) were added to a 400 μl aliquot of the cells. After 15-min incubation in the dark 
- 81 - 
 
at room temperature, stained cells were immediately analyzed by a flow cytometry 
(FACS calibur, BD). A minimum of 10,000 events were collected and analyzed 
using FACS CompTM
 
 software (BD). Annexin V-positive and PI-negative cells 
were defined as early apoptotic cells, while Annexin V-positive and PI-positive 
cells were defined as late apoptotic cells [89].  
3.2.3. Induction and treatment of collagen induced arthritis 
 
All procedures involving animals were performed in accordance with the 
Laboratory Animals Welfare Act, the Guide for the Care and Use of Laboratory 
Animals, and the Guidelines and Policies for Rodent Experiments provided by the 
Institutional Animal Care and Use Committee of Yonsei University Health System, 
Seoul, Korea. Male DBA/1J mice (8 weeks old; Central Lab Animal, Inc., Seoul, 
Korea) were injected intradermally at the tail base with 200 µg bovine type II 
collagen (CII; Chondrex, Redmond, WA, USA) emulsified in Freund’s complete 
adjuvant (1:1, v/v; Chondrex) containing 200 µg Mycobacterium tuberculosis 
H37Ra (Chondrex). Two weeks later, the mice were given intradermal booster 
injections of 100 µg CII in incomplete Freund’s adjuvant (1:1, v/v; Chondrex) 
[90]. Mice were monitored twice weekly for signs of arthritis onset based on paw 
swelling and clinical arthritis scoring on a scale of 0 – 4. The clinical index is the 
sum of the clinical scores for four paws (maximum scores = 16). The evaluated 
paws were scored from 0 to 4 according to the following scale: 0= no evidence of 
erythema and swelling, 1 = erythema and mild swelling, 2 = erythema and mild 
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swelling extending from the ankle to the tarsals, 3 = erythema and moderate 
swelling extending from the ankle to metatarsal joints and 4 = erythema and severe 
swelling encompassing the ankle, foot and digits or ankylosis of the limb (Figure 
36). Each paw was graded by two independent observers and the grades were 
summed, yielding a maximum possible arthritis score of 16 for each animal. Upon 
arthritis development (arthritis score of 8 - 10), mice were randomly arranged to 
each treatment group (n = 3 or n = 5) at 3 weeks after the second CII booster 
injection.  
 
 
Figure 36. Clinical score of CIA mouse [images from http://hookelabs.com]. 
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In the RGD-MTX Au plasmonic NPs experiment, saline (group 1) and  
RGD-MTX-PLGA-Au nanoparticles (groups 3 and 4), and MTX-PLGA-Au 
nanoparticles (group 5) were intravenously administered to the mice, and groups 4 
and 5 were exposed to 1.59 W/cm2
 
 NIR light for 10 min at 1 day after intravenous 
injection of nanoparticles. MTX solution (group 2) with 35 mg/kg was injected 
intraperitoneally once weekly till sacrifice. After that, the mice were observed 
twice weekly during 28 days (n = 5 mice each group, Table 5). 
 
Table 5. Summary of treatments applied to CIA mice for comparative study of 
therapeutic efficacy for RGD-MTX Au plasmonic NPs experiment. 
Group 
(n = 5) Administered content
Dosage of MTX a (mg/kg) 
NIR light 
(W/cm2)b 
Group 1 Saline - - 
Group 2 MTX solution 35 × 4 times - 
Group 3 RGD-MTX-PLGA-Au nanoparticles 0.15 - 
Group 4 RGD-MTX-PLGA-Au nanoparticles  0.15 1.59 
Group 5 MTX-PLGA-Au nanoparticles 0.15 1.59 
 
a Administrated content was injected intravenously by tail vein in a volume 150 μl 
with a nanoparticle concentration of 1 mg/ml.  
b 
 
The arthritis was exposed to NIR light for 10 min with a laser diode (λ = 808 nm) 
at 24 h post-injection. 
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In the MTX-Au/Fe/Au plasmonic NPs experiment, Saline (G1) or MTX-
Au/Fe/Au plasmonic NPs (from G3 to G7) were administered via intravenous tail 
injection. G4, G6, and G7 were also exposed to 1.3 W/cm2
 
 NIR light for 10 min at 
1 day after NP injection. G7 received a second NIR exposure 7 days after the first. 
MTX solution (G2) with 35 mg/kg was injected intraperitoneally twice weekly till 
sacrifice. An external magnetic field was applied to G5, G6 and G7. After that, the 
mice were observed twice weekly during 31 days. (n = 3 mice each group, Table 6). 
 
Table 6. Summary of the treatments applied to CIA mice to compare therapeutic 
efficacy for MTX-Au/Fe/Au plasmonic NPs experiment. 
Group 
(n = 3) Injected content
Dosage of MTX a (mg/kg) 
NIR light 
(W/cm2)
Magnetic field 
b (T)c 
1 Saline - - - 
2 MTX solution 35 × 9 times - - 
3 MTX-Au/Fe/Au plasmonic NPs 0.15 - - 
4 MTX-Au/Fe/Au plasmonic NPs 0.15 1.3 - 
5 MTX-Au/Fe/Au plasmonic NPs 0.15 - 2.3 
6 MTX-Au/Fe/Au plasmonic NPs 0.15 1.3 2.3 
7 MTX-Au/Fe/Au plasmonic NPs 0.15 1.3  × 2 times 2.3 
 
a 
1 mg/ml nanoparticle concentration. 
Administration was performed by intravenous tail vein injection of 150 μl of  
b The arthritis joint was exposed to NIR light with a laser diode (λ = 808 nm) for 10 
min at 24 h post-injection. In group 7, this was repeated 7 days later.  
c The external magnetic field was applied for up to 31 days starting immediately 
after injection.  
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3.3. Results and discussion 
 
3.3.1. Characterization of RGD-MTX Au plasmonic NPs and  
MTX-Au/Fe/Au plasmonic NPs 
 
For targeted delivery, cyclic RGD peptide, which binds αvβ3
In the case of MTX-Au/Fe/Au plasmonic NPs, the NPs with 10-nm Au/ 5-
nm Fe/ 10-nm Au half-shell thickness exhibited the most pronounced absorption 
peak at ~800 nm. NPs lacking the inner or outer Au layer showed absorption peaks 
at a wavelength longer than the biological optical window of 664 - 934 nm.
 integrins 
expressed on angiogenic vascular endothelial cells at sites of inflammation [91], 
was conjugated on the Au surface (RGD-MTX Au plasmonic NPs or MTX-
Au/Fe/Au plasmonic NPs). The visible/NIR absorption spectrum of RGD-MTX Au 
plasmonic NPs exhibited a pronounced peak at approximately 810 nm due to Au 
half-shells. 
 
The size and zeta-potential of prepared nanoparticles dispersed in an aqueous 
medium were measured at 25 °C by using dynamic light scattering (DLS; Zetasizer 
Nano ZS, Malvern Instruments Ltd.). Using dynamic light scattering, RGD-MTX 
Au plasmonic NPs have an average diameter of ~115 nm and the estimated MTX 
Thus, 
MTX-Au/Fe/Au plasmonic NPs were prepared with layers of 10-nm Au/5-nm 
Fe/10-nm Au. Finally, the cyRGD peptide targeting moiety was conjugated to SH-
PEG-COOH modified on the outer Au surface. 
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loading content was about 2.6 wt%. The outer Au surface of the RGD-MTX Au 
plasmonic NPs was found to contain 41.8 μg immobilized RGD peptides/mg of 
NPs. In the case of MTX-Au/Fe/Au plasmonic NPs, similar results were obtained 
(average diameter : 135 nm, MTX loading content : 2.1 wt%, RGD peptides/mg of 
NPs : 19 μg) (Figure 37). 
 
 
 
 
Figure 37. Visible/NIR absorption spectrum and characterization of RGD-MTX Au 
plasmonic NPs (top) or MTX-Au/Fe/Au plasmonic NPs (bottom). 
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When a 0.5 mg/ml solution of MTX-Au/Fe/Au plasmonic NPs was 
irradiated by NIR light (λ = 808 nm, 0.62 W/cm2
     
), the temperature increased to 55 
°C within 10 min (Figure 38), which is comparable to the reported results for Au 
nanorods [92] or nanoshells [93]. These results indicated that these MTX-
Au/Fe/Au plasmonic NPs can be used for photothermal treatment and in vivo NIR 
absorbance imaging. 
 
 
Figure 38. (a) Temperature versus time for the MTX-Au/Fe/Au plasmonic NPs and 
PBS with NIR light irradiation for 10 min. (b) The change of temperature increase 
of MTX-Au/Fe/Au plasmonic NPs for five NIR laser diode on/off cycles (λ = 808 
nm, 0.62 W/cm2
 
, beam diameter d ≈ 3.5 cm). 
 
 
- 88 - 
 
The elemental mapping of an individual MTX-Au/Fe/Au plasmonic NP 
using TEM was shown is Figure 39a. The magnetic properties of MTX-Au/Fe/Au 
plasmonic NPs were also characterized by magnetization-magnetic field curve 
measurement (vibrating sample magnetometer; VSM, Model 7407, Lakeshore). No 
hysteresis was observed, indicating that these NPs are superparamagnetic (Figure 
39b). To determine whether the NPs could be used as contrast for MR imaging, the 
spin-spin relaxation time (T2) and T2-weighted spin-echo MR images were 
measured at 1.5 T for NP solutions of various concentrations (Figure 39c). 
Increasing NP concentrations were associated with increasing 1/T2
 
, indicating that 
MTX-Au/Fe/Au plasmonic NPs can be used as MRI contrast agents as well as NIR 
absorbance imaging agents. 
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Figure 39. (a) Elemental mapping of an individual MTX-Au/Fe/Au plasmonic NP 
using TEM. (b) Magnetization (M–H) curves measured for MTX-Au/Fe/Au 
plasmonic NPs. When the external magnetic field applied, the MTX-Au/Fe/Au 
plasmonic NPs moved toward magnet within 15 min (inset). (c) Magnetic 
resonance data of 1/T2 versus relative NP concentration. The inset shows T2
 
-
weighted images for different NP concentrations. 
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To test the stability of MTX-Au/Fe/Au plasmonic NPs in in vitro condition, 
the stability of NPs in 10% serum at 37 °C was measured by measuring the 
absorbance of NPs solution at 800 nm as a function of time. The absorbance was 
nearly unchanged during 24 h in 10% serum at 37 °C and did not exhibit any 
aggregation, indicating that the NPs were stable in in vitro condition (Figure 40). 
 
 
 
Figure 40. The stability of MTX-Au/Fe/Au plasmonic NPs in 10% serum at 37 °C. 
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Biodegradable PLGA nanoparticles degrade more rapidly with increasing 
temperature [94]. The RGD-MTX Au plasmonic NPs (10 mg) or MTX-Au/Fe/Au 
plasmonic NPs (10 mg) were loaded into a dialysis tube (1 kDa cut-off membrane, 
Tube-O-DIALYZERTM, G-Biosciences, USA) followed by immersion in 10 ml 
PBS with mild constant shaking. During the dialysis, the solution volume was 
maintained constantly by replacing with fresh PBS after each sampling. The release 
experiments for RGD-MTX Au plasmonic NPs were performed with and without 
NIR irradiation (Unique mode 30 k/400/20 (808 ± 3) nm, Jenoptik Co., Germany) 
of 0.38 or 0.53 W/cm2
The release experiments for MTX-Au/Fe/Au plasmonic NPs were also 
conducted with and without two exposures to NIR light of 0.62 W/cm
 for 10 min at the initial time of the experiment at 37 °C.  
2
In order to study the effect of 10-min NIR irradiation on the MTX release 
rate, the release profiles at 37 °C with and without 10-min NIR irradiation were 
measured (Figure 41a). The release rate of MTX from nanoparticles was nearly 
constant without NIR irradiation, resulting in a linear release profile. However, 10 
min NIR irradiation induced a burst release of MTX for 12 h, after which the 
release rate was reduced. These results indicate that the MTX release rate from 
nanoparticles can be controlled by NIR light.  
 for 10 min, 
and 7 days at the start of the experiment at 37 °C. The amount of released MTX 
from the NPs was measured by ultraviolet-visible/NIR spectrophotometer at 304 
nm. The measurements were performed three times for each sample. 
After measuring MTX release, the nanoparticle morphology was examined 
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using a transmission electron microscope (TEM) (Figure 41b). In the absence of 
NIR light, PLGA nanoparticles were not degraded completely and the PLGA that 
was not covered with Au was partly seen. In contrast, when nanoparticles were 
irradiated with NIR light, PLGA nanoparticles were mostly degraded and only Au 
half-shell nanoparticles were clearly observed, supporting photothermally 
controlled drug release.  
 
 
Figure 41. (a) Profiles of MTX release from RGD-MTX Au plasmonic NPs with 
and without NIR irradiation of 0.38 (48 °C) or 0.53 (54 °C) W/cm2 for 10 min at 
the initial time. Data represent mean values for n = 3, and the error bars represent 
standard deviation of the means. (b) TEM images of RGD-MTX Au plasmonic NPs 
measured after MTX release experiments without (top), or with NIR irradiation of 
0.38 (48 °C, middle) or 0.53 (54 °C, bottom) W/cm2 for 10 min at the initial time.  
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Drug release profiles were also measured for the MTX-Au/Fe/Au plasmonic 
NP. Figure 42 shows the drug release profiles from MTX-Au/Fe/Au plasmonic NPs 
with two exposures to NIR light. The first 10-min NIR irradiation caused a 24-h 
burst release of MTX, followed by a slow release. The second NIR irradiation at 7 
days induced another burst release of MTX. These results demonstrated the ability 
to control the MTX release from MTX-Au/Fe/Au plasmonic NPs using NIR light. 
 
Figure 42. Profiles of MTX release from MTX-Au/Fe/Au plasmonic NPs with and 
without NIR irradiation of 0.62 W/cm2 for 10 min at initial time and the second 
NIR was irradiated at 7 days. The temperature increased up to 45 °C after NIR 
irradiation. Data represent mean values for n = 3, and the error bars represent 
standard deviation of the means. 
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3.3.2. In vitro apoptosis analysis 
 
To study the anti-arthritis effect of MTX-Au plasmonic NPs with NIR 
irradiation in vitro, FLS cells were cultured with various treatments and cells on 
apoptotic death were evaluated. The percentage of apoptotic cells from several 
treatments for 48 h and 72 h was evaluated using flow cytometry. After treatment 
of MTX solution of 30 μM, the number of apoptotic cells was significantly 
increased compared to control at 72 h. However, in the case of MTX solution of 
0.13 μM (NPs dose; 1/230 dose of 30 uM MTX solution treatment), the percentage 
of apoptotic cells was decreased compared to MTX solution of 30 μM at 72 h. The 
photothermal treatment using MTX-Au plasmonic NPs with NIR irradiation 
(temperature of culture media increases up to 42 °C), the number of apoptotic cells 
was similar with that of 30 μM MTX solution-treated group at 72 h (Figure 43). 
Therefore, the MTX-Au plasmonic NPs containing a much smaller dose of MTX 
(1/230 of MTX solution) combined with photothermal treatment showed similar 
apoptosis efficacy of FLS cells that of conventional treatment of MTX solution (30 
μM), which indicated that the dose-related MTX side effects could be minimized in 
the treatment of RA. 
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Figure 43. Apoptosis assay results of FLS cells with various treatments. 
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3.3.3. In vivo targeting and retention efficacy 
 
To evaluate the in vivo targeting efficacy, Au plasmonic NPs or Au/Fe/Au 
plasmonic NPs (150 μl, without MTX, 1 mg/ml in PBS) were injected 
intravenously to the CIA mice. The CIA mice were anesthetized by intraperitoneal 
injection of a Zoletil50/Rompun mixture (v/v = 3), and anesthesia was sustained 
during the experiments. NIR absorbance images were obtained using the eXplore 
Optix System (Advanced Research Technologies Inc., Montreal, Canada). The 
absorbance at 710 ~ 750 nm was detected through a fast photomultiplier tube 
(Hammamatsu, Japan) and a time-correlated single photon counting system 
(Becker and Hickl GmbH, Berlin, Germany). The total NIR absorbance intensities 
at the region-of-interest (ROI) in the inflamed paws of CIA mice were calculated 
using the eXplore Optix System software. 
CIA mice treated with MTX-PLGA-Au or RGD-MTX-PLGA-Au 
nanoparticles exhibited a change in in vivo absorbance intensity over time due to 
localization of nanoparticles in the inflamed paws (Figure 44a). The number of 
pixels with absorbance intensity ≥3.82 × 103 a.u. increased up to 24 h after 
intravenous administration, and then decreased, possibly due to a slow release of 
nanoparticles by leaky angiogenic vessels (Figure 44b) [61]. To quantify the 
accumulation of nanoparticles in the inflamed joints, the mass of Au in the 
inflamed paws 24 and 72 h post-injection was measured using an inductively 
coupled plasma mass spectrometer (ICP-MS) (Figure 44b). In two paws of the CIA 
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mice treated with RGD-MTX-PLGA-Au nanoparticles, 0.23 µg of Au was found at 
24 h, corresponding to 0.9% of the injected nanoparticles, whereas 0.16 µg of Au 
(0.7%) was measured in the inflamed paws treated with MTX-PLGA-Au 
nanoparticles. These results indicate that nanoparticles were more effectively 
delivered to the inflamed region via active targeting compared to passive targeting. 
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Figure 44. (a) Time-lapse in vivo NIR absorbance images of inflamed paws in CIA 
mice injected intravenously with MTX-PLGA-Au nanoparticles (150 µl, 1 mg/ml 
dispersed in PBS, left column) or RGD-MTX-PLGA-Au nanoparticles (150 µl, 1 
mg/ml dispersed in PBS, right column). (b) The number of pixels in which the 
absorbance intensity was above 3.82 × 103
 
 a.u. as a function of time for 
nanoparticle-treated mice (left axis), and the amount of Au accumulated in the 
inflamed paws extracted from the nanoparticle-treated mice 24 and 72 h after 
intravenous injection (right axis). The mass of Au was measured using ICP-MS. 
Data represent mean values for n = 3, and the error bars represent standard 
deviation of the means. 
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To evaluate the in vivo retention efficacy, these CIA mice were injected 
intravenously with 150 µl of Au/Fe/Au plasmonic NPs (1 mg/ml stock solution, 
without MTX), and then placed in a mouse cage with or without the Nd-Fe-B 
magnet of 2.3 T (Figure 45). The injected Au/Fe/Au plasmonic NPs were 
monitored by measuring time-lapse in vivo NIR images using an eXplore Optix 
System (Figure 46a). Mice in the cage without the magnet (control group) showed 
increased absorbance intensity in the inflamed paws after NP injection, which 
slowly decreased over time, indicating NP delivery to and accumulation in the 
inflamed paws. In contrast, mice in the cage with the magnet exhibited 
continuously increasing absorbance intensity for up to 7 days, probably due to 
magnetic targeting and enhanced retention of the NPs (Figure 46a). To 
quantitatively compare NP magnetic targeting and retention with and without 
magnetic field application, an inductively coupled plasma mass spectrometer (ICP-
MS) was used to measure the Au accumulated in the inflamed joints (Figure 46b). 
At 7 days after NP injection, the Au mass in the inflamed joints was ~ 0.934 µg 
(1.7% of the injected NPs) for mice in the cage without the magnet, and ~ 1.351 µg 
(2.4% of the injected NPs) for mice in the cage with the magnet. These findings 
support that magnetic field application enhanced the magnetic targeting and 
retention of Au/Fe/Au plasmonic NPs. 
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Figure 45. Photo of magnet cart of CIA mice for the application of magnetic field 
during experiments. The magnet was placed under CIA mice cage. 
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Figure 46. (a) Time-lapse in vivo NIR absorbance images of inflamed paws of CIA 
mice injected intravenously with Au/Fe/Au plasmonic NPs (150 μl, 1 mg/ml in 
PBS) and caged with (+) or without (-) a magnet. (b) Number of pixels in which 
the absorbance intensity was above 4 × 103
 
 arbitrary unit as a function of time for 
Au/Fe/Au plasmonic NP-treated mice caged with (+) or without (-) a magnet (left 
axis). The right axis shows the amount of Au accumulated in the inflamed joints 
extracted from the Au/Fe/Au plasmonic NP-treated mice at 7 days after 
intravenous injection with (+) or without (-) a magnet. The Au mass was measured 
using ICP-MS. Error bars represent standard deviation (n = 3, *p < 0.05). 
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I also analyzed MR images of the CIA mice treated with Au/Fe/Au 
plasmonic NPs and cage with or without the magnet (Figure 47). T2-weighted MR 
images were collected using a 9.4-T 20-cm-bore MRI system (Bruker Biospin, 
Ettlingen, Germany) equipped with a rat brain surface coil (4 ch). Animal imaging 
was performed under inhalational anesthesia with isofluorane (3% induction and 1% 
maintenance with 100% O2 at a 1,000 ml/min constant flow rate). T2-weighted MR 
images were acquired at 1 day and 7 days after intravenous injection of Au/Fe/Au 
plasmonic NPs (150 μl, without MTX, 1 mg/ml in PBS). T2 map and T2 
Since 1/T
color map 
images were processed with the Image Sequence Analysis Tool of Bruker 
Paravision 5.1 (Bruker Biospin, Ettlingen, Germany). 
2 increased with increasing Au/Fe/Au plasmonic NPs concentration, 
lower T2
 
 values represented more NPs. In the control group, similar amounts of 
NPs were accumulated in the inflamed paws at 1 and 7 days after NP injection. In 
contrast, the mice caged with the magnet showed larger NP amounts accumulated 
in the inflamed paw, and the NP amount increased over time (Figure 47a and b), as 
seen in the in vivo NIR absorbance images. These results confirmed that external 
magnetic fields resulted in greater Au/Fe/Au plasmonic NP delivery to the 
inflamed paws and enhanced NP retention. 
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Figure 47. (a) Time-lapse in vivo T2-weighted MR images of inflamed paws of 
CIA mice injected intravenously with Au/Fe/Au plasmonic NPs (150 μl, 1 mg/ml 
in PBS) with (+) or without (-) a magnet. (b) T2
 
-weighted MR signal as a function 
of time for Au/Fe/Au plasmonic NPs-treated mice with (+) or without (-) a magnet. 
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3.3.4. In vivo therapeutic effects  
 
First, in vivo local heat generation by NIR irradiation was investigated prior 
to the study of in vivo therapeutic effects of NPs.  
Heat is locally generated by NIR irradiation because the Au half-shells have 
an absorption peak in the NIR region. To determine the temperature increase upon 
NIR exposure, the temperature of CIA mice treated with saline, MTX-Au 
plasmonic NPs or RGD-MTX-Au plasmonic NPs 24 h post-injection was measured 
using a thermal imaging camera (FLIR-T250, FLIR, Sweden) when the right 
inflamed paw was exposed to 1.59 W/cm2
 
 NIR light for 10 min using a laser diode 
(λ ≈ 808 nm). Before NIR exposure, the temperature was approximately 36 °C 
over the whole body, corresponding to the body temperature of the mouse. 
However, after 10 min of NIR irradiation, the temperature of the irradiated paw 
increased to 39, 42, and 48 °C for the mice treated with saline, MTX-PLGA-Au 
nanoparticles, and RGD-MTX-PLGA-Au nanoparticles, respectively (Figure 48a). 
In the case of MTX-Au/Fe/Au plasmonic NPs, NIR irradiation increased the 
temperature of the inflamed paw to ~ 45 °C (Figure 48b). These temperatures are 
not high enough to induce irreversible tissue damage.  
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Figure 48. (a) Thermal images of CIA mice treated with saline, MTX-PLGA-Au 
nanoparticles (150 µl, 1 mg/ml dispersed in PBS), or RGD-MTX-PLGA-Au 
nanoparticles (150 µl, 1 mg/ml dispersed in PBS) before and after NIR exposure 
(1.59 W/cm2, 10 min) of the right paw. (b) Thermal images of CIA mice treated 
with saline, MTX-Au/Fe/Au plasmonic NPs (150 µl, 1 mg/ml in PBS) before a
nd after NIR irradiation (1.3 W/cm2
 
, 10 min) of the inflamed paws. The thermal 
images of MTX-Au/Fe/Au plasmonic NPs injected CIA mouse for NIR irrad
iation were acquired using thermal imaging camera (FLIR-T250, FLIR, Swed
en). 
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In addition, to examine the in vivo local MTX release from MTX-PLGA-Au 
plasmonic NPs under NIR irradiation, rhodamine loaded nanoparticles with Au 
half-shell (Rhodamine-PLGA Au Plasmonic NPs) were synthesized by similar 
procedure of MTX-PLGA Au Plasmonic NPs.  
Total 50 μl of rhodamine solution (5 mg/ml Rho) was injected into hind foot 
pad of two CIA mice. The same volume of Rhodamine-PLGA Au Plasmonic NPs 
(4 μg/ml Rho) was subcutaneously injected into hind foot pad of two CIA mice, 
and these limbs were irradiated with NIR 1.96 W/cm2. The amount of rhodamine 
per same volume in NPs is about 1/1200 of rhodamine solution. One mouse from 
each group was sacrificed 1 h after injections, and the other from each group was 
sacrificed 24 h after injection. All samples were counterstained with 4’,6-
diamidino-2-phenylinodole (DAPI). The paws embedded in OCT compound and 
horizontally sectioned. Rhodamine accumulation was surveyed for 1 h and 24 h 
following the injection. Since MTX could not excited by laser, a red fluorescence 
dye, rhodamine, was loaded into the PLGA-Au plasmonic NPs. In case of the 
mouse injected with rhodamine solutions, rhodamine were prominently detected 
after 1 hour, but not detected after 24 h because rhodamine was rapidly cleared 
from the body. In contrast, scanty rhodamine was detected in paw after injection of 
rhodamine-PLGA-Au plasmonic NPs. However, after NIR irradiation for 10 min at 
rhodamine-PLGA-Au plasmonic NPs injected site, the released rhodamine was 
detected in the injected paw at 1 h. After 24 h of NIR irradiation, rhodamine was 
more detected in arthritis paw (Figure 49). These results confirm that the loaded 
rhodamine within the rhodamine-PLGA-Au plasmonic NPs can be locally and 
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slowly released and sustained for a long time in the locally NIR irradiated areas in 
in vivo system. 
 
Figure 49. (a) Thermal image of CIA mice subcutaneously treated with rhodamine-
PLGA Au plasmonic NPs (50 μl, 4 μg/ml Rho) after NIR irradiation at the right 
paw. (b) Time-lapse immunofluorescence images of arthritis hind foot pads after 
injected with rhodamine solution or rhodamine-PLGA Au plasmonic NPs (red : 
rhodamine, blue : 4',6-diamidino-2-phenylindole (DAPI)). 
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Next, I confirmed the in vivo therapeutic effects after RGD-MTX-Au 
plasmonic NPs or MTX-Au/Fe/Au plasmonic NPs treatment. In order to 
investigate the therapeutic effects of RGD-MTX-Au plasmonic NPs, comparative 
efficacy studies were carried out (Figure 50a). CIA mice were divided into five 
groups (n = 5 mice per group), and 150 µl of each treatment was administered via 
intravenous tail injection as summarized in Table 5. For MTX, 35 mg/kg was 
injected four times every week. In the mice treated with RGD-MTX-PLGA-Au 
nanoparticles (0.15 mg/kg MTX) without NIR irradiation (group 3), the clinical 
indices slowly decreased until about day 20 and then increased again, though they 
were lower than those of the saline-treated mice (group 1). However, when the 
mice were treated with RGD-MTX-PLGA-Au nanoparticles (0.15 mg/kg MTX) 
and exposed to 1.59 W/cm2 NIR light for 10 min at 24 h after intravenous injection 
(group 4), the clinical indices were lower than those of the mice treated with free 
MTX solution four times every week (group 2), which might be due to 
photothermally controlled drug release. For group 3, MTX was slowly released 
from nanoparticles; therefore, the released dosage of MTX was probably at a sub-
therapeutic level, resulting in the small therapeutic effects. In contrast, the 
temperature of the inflamed paw exposed to NIR light increased to 48 oC, leading 
to a release of more than 20% of the loaded MTX within 12 h. This dosage of 
MTX released locally in the inflamed paw was likely above the therapeutic dose, 
so high therapeutic efficacies were obtained for group 4. The nanoparticles injected 
into group 4 contained only 0.15 mg/kg of MTX, which was 1/930 of the dose in 
group 2, suggesting that the nanoparticle-based treatment would contribute to 
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minimizing dosage-related side effects. The effect of NIR power density on 
therapeutic efficacy was also investigated (Figure 50b). The lowest clinical indices 
were obtained with 1.59 W/cm2 NIR irradiation for 10 min. When the inflamed 
paws were exposed to 1.91 W/cm2
 
 NIR light, the clinical index was not reduced. 
These findings implied that moderate heat might relieve RA, but too much heat 
aggravated it.  
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Figure 50. (a) Clinical index versus time for CIA mice injected intravenously with 
saline (group 1), MTX solution (35 mg/kg × 4 times, group 2), RGD-MTX-PLGA-
Au nanoparticles (0.15 mg/kg of MTX, group 3), RGD-MTX-PLGA-Au 
nanoparticles (0.15 mg/kg of MTX) with NIR irradiation (1.59 W/cm2, 10 min, 
group 4), or MTX-PLGA-Au nanoparticles (0.15 mg/kg of MTX) with NIR 
irradiation (1.59 W/cm2, 10 min, group 5). Error bars represent standard deviation 
(n = 5). Clinical indices were significantly different among groups (*p < 0.0001).  
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To confirm the in vivo therapeutic effects after RGD-MTX-Au plasmonic 
NPs treatment, micro-computed tomography (CT) was also performed. Each 
experimental mice paws were scanned using micro-CT system (NFR Polarys-G90, 
Nanofocusray Int, Iksan, Korea). Images were acquired at 80 kVp, 150 mA, and 5 
s/frame, with 360 views. The estimated radiation dose was approximately 6.9 mGy 
using image acquisition protocol. Scanned paws reconstructed into the three-
dimensional structure and evaluated by NFR Polarys software (Exxim Computing 
Corporation, Pleasanton, USA). To confirm volumetric change of arthritis joints, 3-
dimensional bone volume (BV) including phalanges and metatarsal bones was 
measured using Aquarius software (version 4.4.6, TeraRecon, Inc.) 
Three-dimensional micro-CT was performed to assess bony changes in the 
paws of CIA mice (Figure 51). The paws of saline-treated CIA mice exhibited 
severe bone destruction. On the other hand, the bony structures were relatively well 
preserved in the paws of groups 2 (MTX solution) and 4 (RGD-MTX-Au 
plasmonic NPs with NIR irradiation). To determine the extent of bone preservation, 
the bone volume of the paws of CIA mice was measured. The bone volume in the 
treated group tended to be better preserved. 
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Figure 51. Micro-computed tomography (CT) scan of paws from the normal mouse 
(NA) and CIA mice after each treatment. (a) Three dimensional reconstruction of 
micro-CT imaging of the paws of CIA mice. (b) Bone volume of paws of CIA mice. 
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Next, clinical indices of MTX-Au/Fe/Au plasmonic NPs-treated mice were 
investigated. The CIA mice were divided into seven groups (n = 3 in each group) 
and treated as summarized in Table 6. When arthritis was fully developed (group 
mean clinical index of 8 - 10), the mice were injected with saline (G1), MTX 
solution (G2), or MTX-Au/Fe/Au plasmonic NPs (G3-G7). G2 received twice 
weekly intraperitoneal injections of 35 mg/kg MTX solution till sacrifice. G3 
through G7 received a single intravenous tail vein injection of NP solution 
containing 0.15 mg/kg of MTX (150 μl, 1 mg/ml in PBS). G5, G6, and G7 were 
caged with the Nd-Fe-B magnet of 2.3 T, while G3 and G4 were caged without the 
magnet. G4 and G6 were irradiated with NIR light (1.3 W/cm2) for 10 min at 1 day 
after injection. G7 was exposed to NIR light (1.3 W/cm2
Compared to saline-treated mice (G1), all other groups showed decreased 
clinical indices with some variations observed depending on the day. 
Photothermally treated mice (G4 and G6) generally exhibited lower clinical indices 
than mice treated with NPs and unexposed to NIR light (G3 and G5), regardless of 
magnetic field application. This implied that the MTX burst release upon NIR 
irradiation contributed to decreasing the clinical index more effectively compared 
to the slow MTX release without NIR irradiation. The photothermally treated mice 
(G4 and G6; 0.15 mg/kg MTX) showed therapeutic efficacy comparable to the 
MTX treated mice (G2; 35 mg/kg × 9 times = 315 mg/kg), with only 0.05% of the 
MTX dosage used in G2. Interestingly, a second exposure to NIR light at the 7th 
) for 10 min on two 
occasions: at 1 and 7 days after injection. NIR irradiation increased the temperature 
of the inflamed paw to ~ 45 °C (Figure 48b).  
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day in the presence of external magnetic field (G7) achieved higher therapeutic 
effects (Figure 52a and b). Therefore, magnetic targeted chemo-photothermal 
treatment provides higher therapeutic efficacy compared with conventional or 
chemo-photothermal treatment. 
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Figure 52. (a) Clinical index of the paws of CIA mice after treatment with saline 
(G1), MTX solution (35 mg/kg × 9 times; G2), or MTX-Au/Fe/Au plasmonic NPs 
(0.15 mg/kg of MTX; G3), as well as after treatment with MTX-Au/Fe/Au 
plasmonic NPs (0.15 mg/kg of MTX) followed by NIR irradiation (1.3 W/cm2, 10 
min; G4), followed by caging with a magnet (2.3 T, 31 days; G5), followed by NIR 
irradiation and a the magnet (1.3 W/cm2, 10 min and 2.3 T, 31 days; G6), or 
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followed by two exposure to NIR irradiation and a magnet (1.3 W/cm2
(0.15 mg/kg of MTX) with repeated NIR irradiation and under the magnet (1.3 
W/cm
 × 2 times, 
10 min × 2 times and 2.3 T, 31 days; G7). Error bars represent the standard 
deviation (n = 3). *p < 0.005 compared to the saline treated mice (G1). (b) Photo of 
paws from the CIA mice before (0 d) and after treatment (31 d) with saline (G1), 
MTX solution (35 mg/kg × 9 times, G2), and MTX-Au/Fe/Au plasmonic NPs  
2
 
 × 2 times, 10 min × 2 times and 2.3 T, 31 days, G7). The same mouse of 
each group (G1, G2, and G7) was observed during 31 days. 
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Finally, histological examinations of joints 28 days after intravenous 
injection of RGD-MTX-Au plasmonic NPs were performed (Figure 53a). The mice 
were anesthetized and sacrificed 28 days (or 32 days for the MTX-Au/Fe/Au 
plasmonic NPs experiment) after each treatment. Joints were removed for 
histopathological examination and fixed in 10% buffered formalin-saline at 4 °C 
for 1 week. The joints were decalciﬁed in Calci -Clear Rapid solution (National 
Diagnostics, Atlanta, USA), and specimens were processed for parafﬁn embedding. 
Joint tissues were embedded in paraffin blocks and 5-µm-thick paraffin sections 
were mounted on a glass slide for hematoxylin and eosin (H&E) and safranin-O 
staining. The joint sections were scored for changes in synovial inflammation, and 
cartilage erosion, all on a scale of 0-4, which were evaluated as previously 
described 
Group 1 exhibited marked synovial inflammation and cartilage erosion, 
whereas the extent of synovial inflammation and cartilage erosion was reduced in 
groups 2 and 4 (Figure 53b). Pro-inflammatory cytokines, including IL-1β, IL-6, 
[95]. Deparaffinized sections were incubated with specific antibodies 
directed against IL-Iβ, IL-6 (Santa Cruz Biotechnology, Santa Cruz, USA), or 
TNF-α (Hycult Biotechnology, Uden, Netherlands), followed by the appropriate 
peroxidase/DAB secondary antibodies (DAKO, Glostrup, Denmark). Expression of 
the different cytokines in the synovial tissue was scored semiquantitatively on a 4-
point scale [96]. A score of 0 represented no expression, 1 mild expression, 2 
moderate expression, and 3 abundant expression of a cytokine. All histologic 
analyses were preformed independently and blindly by two individual assessors, 
and the average of their scores was calculated. 
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and TNF-α, are centrally involved in the pathogenesis of RA and their expressions 
are closely related to the inflammatory activity of RA. Immunohistochemical 
staining showed increased TNF-α, IL-6, and IL-1β expression around the joint in 
group 1, whereas they were significantly decreased in groups 2 and 4 (Figure 53b). 
There were no significant differences between group 2 and group 4. 
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Figure 53. (a) Histology of joint tissues extracted from a normal mouse (NA) and 
CIA mice 28 days after each treatment. H&E (synovial inflammation, original 
magnification, × 40, × 100), safranin-O (cartilage erosion, original magnification, × 
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100), and immunohistochemical staining for IL-1β, IL-6 and TNF-α (original 
magnification, × 400) stained representative joint sections from experiment. (b) 
Semi-quantitative analysis of histopathological evaluation (synovial inflammation 
and cartilage erosion) and immunohistochemical staining for IL-1β, IL-6 and TNF-
α in CIA mice. The bars represent the standard deviation and asterisks (*) represent 
significance compared to untreated mice with *p < 0.05 (n = 5).  
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In the case of MTX-Au/Fe/Au plasmonic NPs, G1 showed inflammatory cell 
infiltration, bone erosion, and synovial proliferation, each of which was 
significantly decreased in G6 and G7. The results in G6 and G7 were comparable 
or superior to in the MTX treatment group (G2) (Figure 54a and b). 
 
 
Figure 54. (a) Histology of joint tissues extracted from a normal mouse (NC) and 
from CIA mice 32 at days after each treatment. H&E-stained representative 
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joint sections from the experiment are shown (synovial inflammation, original 
magnification, 100×). (b) Semiquantitative analysis of histopathological evaluation 
(cell infiltration, bone erosion, and synovial proliferation) of CIA mice. Error bars 
represent the standard deviation (n = 3). *p < 0.05 compared to the saline treated 
mice (G1). 
 
3.3.5. In vivo toxicity  
 
In order to study the normal tissue toxicity caused by the RGD-MTX-Au 
plasmonic NPs, histological examinations of major organs (liver, spleen, kidney, 
lung, and heart) were investigated at 28 days post-injection (Figure 55a). No tissue 
damage was evident compared to the NPs-free control, implying that NPs 
accumulating in major organs did not induce in vivo toxicity.  
Histological examinations of major organs were also performed at 32 days 
post-injection to investigate the influence of MTX-Au/Fe/Au plasmonic NPs on 
major organs (Figure 55b). Compared to the negative control, G7 showed no 
apparent tissue damage, implying that the NPs accumulated in major organs did not 
induce in vivo toxicity.  
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Figure 55. (a) Histological sections of major organs extracted 28 days after 
intravenous injection of saline (top) or RGD-MTX-PLGA-Au nanoparticles with 
NIR irradiation (bottom, group 4). Images were acquired at 400× magnification. (b) 
Histological sections of major organs extracted 32 days after intravenous injection 
of saline (top) or MTX-Au/Fe/Au plasmonic NPs (0.15 mg/kg of MTX) with 
repeated NIR irradiation and under the magnet (1.3 W/cm2
 
 × 2 times, 10 min × 2 
times and 2.3 T, 31 days, G7) (bottom). H&E-stained images were acquired at 
400× magnification. 
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A hematological analyses, including white blood count (WBC), platelets, 
aspartate aminotransferase (AST), alanine aminotransferase (ALT), blood urea 
nitrogen (BUN), and creatinine in blood were performed after MTX-Au/Fe/Au 
plasmonic NPs treatment (Table 7). Compared to the negative control, G3, G5, and 
G6 showed no significant toxicity supporting that the MTX-Au/Fe/Au plasmonic 
NPs caused no toxicity. 
 
Table 7. Hematological ananlyses as white blood count (WBC), platelets, aspartate 
aminotransferase (AST), alanine aminotransferase (ALT), blood urea nitrogen 
(BUN), and creatinine in blood (data are given as mean value; n = 3 per each 
group). 
Parameters Reference range 
Negative 
control 
MTX- 
Au/Fe/Au 
Plasmonic  
NPs (G3) 
MTX- 
Au/Fe/Au 
Plasmonic  
NPs + 
Magnet (G5) 
MTX- 
Au/Fe/Au 
Plasmonic  
NPs + 
Magnet + 
NIR (G6) 
WBC  
(K/ul) 4,000 ~ 15,000 4,240  4,650  4,055  4,013  
Platelets 
(10
3 600 ~ 1,000 
K/ul) 
606 812  904  792  
AST  
(U/l) 54 ~ 298 81 86  121  123  
ALT  
(U/l) 17 ~ 77 33 31  50  29  
BUN  
(mg/dl) 8 ~ 33 25.3 18.3  16.0  19.1  
Creatinine 
(mg/dl) 0.2 ~ 0.9 0.46 0.20  0.20  0.20  
       
WBC : white blood count, AST : aspartate aminotransferase, ALT : alanine 
aminotransferase, BUN : blood urea nitrogen. 
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An important concern for nanoparticle-based treatments is whether the 
injected nanoparticles accumulate in organs or are cleared from the body. To 
investigate the biodistribution of RGD-MTX-PLGA-Au nanoparticles, the Au 
accumulated in major organs 1, 3, and 28 days after intravenous injection were 
measured using ICP-MS. Briefly, these tissues were dissolved in an aqua regia 
during overnight at 80 - 90 °C and re-heating at 120 – 130 °C was conducted for 12 
h. The amount of ionized Au was analyzed by ICP-MS (PerkinElmer Nexion 300S). 
Nanoparticles were efficiently taken up by the liver, lung, and spleen that are 
related with the reticuloendothelial system (RES), with less accumulation in the 
kidney or heart. However, most nanoparticles were cleared from the body after 28 
days (Figure 56a). In the case of MTX-Au/Fe/Au plasmonic NPs, most NPs were 
cleared from the body after 28 days regardless of external magnetic field 
application (Figure 56b). 
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Figure 56. (a) Tissue distribution of RGD-MTX-Au plasmonic NPs in major organs 
at different times. The amount of Au was measured by ICP-MS (t-test, one-tailed, 
paired, liver, p = 0.026; lung, p = 0.005; spleen, p = 0.031; heart, p = 0.002; kidney, 
p = 0.039). Error bars represent standard deviation (n = 5). (b) Tissue distribution 
of NPs in major organs (liver, spleen, and kidney) at different times. The amount of 
Au was measured by ICP-MS. Error bars represent standard deviation (*p < 0.05, n 
= 3). 
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3.4. Summary 
 
The therapeutic effects of RGD-MTX-Au plasmonic NPs and MTX-
Au/Fe/Au plasmonic NPs in CIA mice were investigated. When the nanopartlces 
were injected intravenously into the CIA mice, in vivo NIR absorbance images 
revealed that the nanoparticles selectively accumulated in the inflamed region. 
Upon NIR irradiation (1.59 W/cm2, 10 min), the temperature of the inflamed paw 
increased to 48 o
In addition, the MTX-Au/Fe/Au plasmonic NPs were successfully fabricated 
and shown to be applicable for multimodal imaging and magnetic targeted chemo-
photothermal treatment. Following intravenous injection of these NPs into CIA 
mice, in vivo NIR absorbance and MR images revealed NP accumulation in the 
inflamed paws, which was enhanced under the external magnetic field. NIR 
irradiation increased the temperature of the exposed area and accelerated the MTX 
release rate from the NPs, allowing the chemo-photothermal treatment. 
Furthermore, combination with consecutive NIR irradiation and external magnetic 
C, leading to the burst release of MTX from the nanoparticles. 
Compared to conventional treatment with MTX, the RGD-MTX-Au plasmonic 
NPs-based treatment combined with NIR irradiation had greater therapeutic 
efficacy with a much smaller dosage of MTX in the nanoparticles. These results 
demonstrate that the targeted chemo-photothermal treatment using multifunctional 
nanoparticles is a useful and effective strategy for maximizing the therapeutic 
efficacy and minimizing dosage-related side effects in the treatment of RA. 
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field application resulted in higher therapeutic efficacy compared to conventional 
treatment, despite the use of a much smaller MTX dosage (0.05%) in the injected 
NPs. 
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Chapter 4.  
Multi walled carbon nanotubes electrodes 
: application in discrimination of lipid region in  
ex vivo atherosclerosis using capacitance imaging 
 
 
 
 
 
4.1. Introduction 
 
4.1.1. Atherosclerosis 
  
Atherosclerosis (AS) which is characterized by the accumulation of lipids in 
artery is the most common cause of stroke and myocardial infarction (heart attack) 
[97]. During AS progression, the lumen of the artery was narrowed due to the 
atherosclerotic plaque, resulting in the reduction of blood supply to organs, 
especially heart and brain. The atherosclerotic plaque begins with a fatty streak 
originated from the accumulation of foam cells. After then, a smooth muscle cell 
and T cell lead to the state of chronic inflammation and then thrombus was formed 
in the lumen accompanied with necrotic core. Eventually, the lumen was narrowed 
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and the blood flow to the organ was reduced (Figure 57) [98]. Foam cells, which 
are hallmark of initiation of AS, are formed from the lipoproteins-contained 
macrophages. The macrophage-derived foam cells, which are formed by oxidized 
low-density lipoprotein (oxLDL), are the crucial marker for early AS. So, the 
confirmation of foam cells formation is critical for evaluating AS. Observation of 
foam cell formation is usually conducted by conventional Oil Red O (ORO) 
staining method for lipid-laden macrophages in both in vitro and ex vivo [99]. 
 
 
 
Figure 57. Progression of atherosclerosis [98]. 
 
 
The AS has been studies using animal models, such as mice, rabbits, and 
pigs. Mice deficient in apolipoprotein E (apoE-/-) or the low-density lipoprotein 
(LDL) receptor have been used for studies of AS. The accumulation and 
aggregation of lipoprotein particles were observed in the intima of artery after 
feeding of high-fat diet as shown in Figure 58a and b. After then, monocytes 
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transmigrate into the intima and differentiate into macrophages. Foam cells formed 
from the lipoproteins-contained macrophages (Figure 58c and d). In other words, 
foam cells are ‘cholesterol-engorged macrophages’. The macrophage-derived foam 
cells, which are formed by oxidized low-density lipoprotein (oxLDL), is the crucial 
marker for AS. So, the assessment of foam cells formation is critical for evaluating 
AS. Observation of foam cell formation is usually conducted by Oil Red O (ORO) 
staining of lipid-laden macrophages in both in vitro and ex vivo. The lipids in foam 
cells affect to the necrotic core of the lesions after foam cells die. The lesions 
continue to grow and enter at the shoulder of the vessel (Figure 58e), eventually 
lead to AS.  
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Figure 58. Initiation and progression of atherosclerotic plaques [97]. (a) The freeze-
etch electron micrograph image of the accumulated 23-nm LDL particles (circle) in 
the matrix of a rabbit atrioventricular valves after incubation with LDL (inset). 
Scale bar: 0.1 μm. Abbreviations: MEMB, plasma membrane; CYTO, cytoplasma. 
(b) The freeze-etch electron micrograph image of the aggregated lipoprotein of 
rabbit intima after LDL treatment. Asterisk indicates matrix and collagen fibrils. 
Scale bar: 0.2 μm. (c) The electron micrograph image of a cross-section of the aorta 
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in apoE-/-
 
 mouse shows transmigration of monocyte into the intima (int). Asterisk 
indicates a cluster of lipid. Arrows and arrowheads indicate monocyte and 
endothelial cells, respectively. Scale bar: 0.5 μm. (d) The freeze-etch electron 
micrograph image of the cytoplasm of a macrophage in the intima of a rabbit fed a 
high-fat diet shows the formation of foam cell. Large lipid droplets with cholesterol 
esters (ce) were observed. Arrows and asterisk indicate lipid-filled compartments 
and aggregated LDL, respectively. Scale bar: 0.5 μm. (e) Light micrograph image 
of a section of an advanced human coronary atherosclerotic lesion. This sample 
was immunostained for the macrophage specific antigen EMB-11 (red). 
Abbreviations: A, adventitia; I, intima; IEL, internal elastic lamina; M, media. 
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Up to date, the diagnostic techniques for AS, such as angiography, computed 
tomography (CT), and intravascular ultrasound (IVUS) were mainly used in clinic. 
However, these techniques were expensive methods and needed experts to operate 
them, and some patients have side effects for the contrast agents used in 
angiography.  
Some groups have reported the detection of lipid-rich atherosclerotic plaque 
in ex vivo using electrochemical impedance sensors. In these studies, impedance 
sensors, such as linear 4-point microelectrode which attached to balloon catheter, 
concentric bipolar microelectrodes, and flexible concentric bipolar microelectrodes 
with balloon catheter were fabricated [100-101]. Electrochemical impedance 
spectroscopy (EIS) which measures the alternating current (ac) impedance of tissue 
has shown that lipid-rich atherosclerotic plaque tissue has distinct electrochemical 
properties. Lipid-rich atherosclerotic plaque tissue has exhibited increase in 
frequency-dependent impedance compared to atherosclerotic plaque-free tissue in 
rabbits and human ex vivo. These studies have demonstrated that lipid-rich 
atherosclerotic plaque could be detected using EIS sensor in ex vivo. However, 
detection and visualization of lipid region in atherosclerotic plaque remain an 
unmet. In addition to detect the lipid, it is important to visualize the lipid region in 
high resolution for the early diagnosis of AS. 
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4.1.2. Principle of capacitance imaging 
 
To overcome this issue, I have developed capacitance imaging technique for 
the detection and visualization of foam cells that are filled with lipids in 
atherosclerotic plaque ex vivo. In previous study, real-time monitoring of adipocyte 
differentiation using capacitance sensor have been reported [102]. Lipid droplets 
contained adipocytes (3T3-L1 cell) were differentiated after FFA (free fatty acid) 
treatment. Because lipid droplets in adipocytes have unique dielectric constant (ε), 
capacitance could be measured via the relationship: C = εA/d, where A is the 
electrode area and d is the distance between the two electrodes (Figure 59a). I 
anticipate that it is also possible to detect the lipid filled foam cells in 
atherosclerotic plaque ex vivo by measuring capacitance (Figure 59b). Moreover, 
lipid filled foam cells could be visualized from the capacitance values.  
Here, I report capacitance imaging technique for discrimination of lipid 
region in atherosclerotic plaque ex vivo using polypyrrole-coated multi walled 
carbon nanotubes multi electrodes array (PPy-MWNTs-MEA). Compared to TiN 
multi electrodes array (TiN-MEA), enhanced contact between electrodes and 
atherosclerotic plaque interface, low electrode impedance, and improved 
mechanical stability leads to the apparent discrimination of lipid region using PPy-
MWNTs-MEA. I also demonstrate the feasibility of flexible multi electrodes array 
(F-MEA) for identification of lipid region.  
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Figure 59. (a) Capacitance measurements for adipocytes, (b) Capacitance imaging 
of lipid region in atherosclerosis. 
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4.2. Experimental details 
 
4.2.1. Fabrication of polypyrrole-coated MWNTs MEA 
 
Fabrication of the MWNTs MEA consisted of 60 electrodes which have 30 
µm in diameter with 100 µm distance between electrodes proceeded in three steps: 
formation of bottom electrode, passivation and catalyst patterning, and MWNTs 
growth. The positive photoresists were spin-coated on quartz substrate (Thickness : 
0.5 mm) and the bottom electrode was fabricated by using conventional 
photolithography and lift-off. The Ti (5 nm) adhesion layer followed by Pt (100 nm) 
were deposited using sputter. After bottom electrode patterning, the passivation 
patterning were performed by photolithography followed by deposition of SiO2 
(200 nm) using e-beam evaporator and lift-off. Lastly, patterns for catalyst position 
were introduced on the bottom electrode. The SiO2 (20 nm) and Cr (5 nm)/Co(5 
nm) were successively deposited using e-beam evaporator. The Co (5 nm) was used 
as catalyst layer. Finally, the MWNTs were grown by the plasma-enhanced 
chemical vapor deposition (PECVD) at 650 °C for 30 min with C2H2
TiN MEA (60MEA200/30iR-ITO) consisted of 60 electrodes (30 µm in 
diameter, including 1 reference electrode) with 200 µm distance between electrodes 
 (60 sccm) as 
a carbon source. A hydrogen (160 sccm) was introduced in the chamber during 
MWNTs growth process and the pressure of the chamber was kept at 5.99 Torr 
with 70 W RF plasma. 
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was purchased from Multichannel systems 
(Germany, http://www.multichannelsystems.com).  
To fabricate flexible MEA, thin films of single walled carbon nanotubes 
(SWNTs; PureTubes™, Nanointegris) were formed on membrane filter 
(VSWP04700, Millipore, 0.025 µm) using vacuum filtration followed by transfer 
to polyethylene terephthalate (PET) substrate. The membrane filter was removed 
by acetone. Then, the SWNTs patterns were made by using O2
To electro-deposition of pyrrole on MWNs, pyrrole (99%, extra pure) was 
purchased from Acros Organics (New Jersey, USA). Pyrrole was electrodeposited 
onto MWNTs-MEA under the optimized conditions from an aqueous solution of 
0.25 M pyrrole mixed with 0.1 M NaCl by using three-electrode system. The 
working electrode was MWNTs-MEA and the counter and reference electrodes 
were a Pt wire and an Ag/AgCl electrode (in a 3.5 M KCl solution), respectively. 
The Electro-deposition of pyrrole was performed using a potentiostat/galvanostat 
(Model 263 A, Princeton Applied Research, USA) at 0.75 V (vs. saturated calomel 
electrode (SCE)) for 1 min. 
 plasma (30 W, 20 
s). A Cr (15 nm)/Au (100 nm) electrodes were patterned for the connection to LCR 
meter. The photoresist was used to passivate for SWNTs electrode while opening 
the sensing area. After then, pyrrole was elctro-deposited on the SWNTs electrode. 
The same structure of MEA consisted of 60 electrodes which have 30 µm in 
diameter with 100 µm distance between electrodes were constructed on the flexible 
PET substrate. 
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4.2.2. Animals and preparation of atherosclerosis ex vivo sample 
 
Female apoE-/- mice (C57BL/6, 5 weeks old) were supplied by Orient Bio 
INC. (Central Lab Animal, Inc., Seoul, Korea). All animal experiments were 
performed in accordance with the Korean Food and Drug Administration (KFDA) 
guidelines. Protocols were reviewed and approved by the Institutional Animal Care 
and Use Committee (IACUC) of the Yonsei Laboratory Animal Research Center 
(YLARC). All mice were maintained in a specific pathogen-free facility at the 
YLARC. The mice were fed a high fat diet (HFD) supplemented with 2% 
cholesterol, 0.5% w/w cholate and 10% w/w lard oil for 4 weeks. At the ending of 
the HFD period, the mice were sacrified, and the aorta and heart tissues were 
dissected. These ex vivo samples were fixed using formaldehyde followed by 
stained with Oil Red O (Sigma-Aldrich Chemical Co., USA) solution.  
 
4.2.3. Capacitance measurements 
 
Capacitance, phase, and contact impedance were measured using an LCR 
meter (Agilent 4294A) with a data acquisition/switching unit (Agilent 34970A) 
connected to the LCR meter, respectively. Data were acquired under an ac voltage 
of 10 mV at a frequency sweep from 10 kHz to 100 kHz (or 500 Hz to 2900 Hz). 
During the measurements, a PDMS (polydimethylsiloxane) was mounted on the 
atherosclerotic plaque ex vivo sample to enhance contact between ex vivo sample 
and electrodes. All measurements were performed at ambient condition. 
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4.3. Results and discussion 
 
4.3.1. Characterization of multi electrodes array (MEA) 
 
Figure 60a shows a schematic diagram of the PPy-coated multi walled 
carbon nanotubes multi electrodes arrays (PPy-MWNTs-MEA). Standard 
photolithography and lift-off process were continuously used to fabricate Ti/Pt 
bottom electrodes, SiO2 passivation layer, and Cr/Co pattern. Prior to the 
deposition of Cr/Co layer, 20 nm thickness of SiO2 was deposited to Pt electrodes 
to prevent damage of Pt electrodes in high temperature (650 °C) during MWNTs 
growth process. To enhance the growth of MWNTs, plasma treatment was 
conducted during the synthesis process. The scanning electron microscope (SEM) 
image as shown in Figure 60b indicates that the MWNTs electrodes which 30 µm 
in diameter with 100 µm distance between electrodes were fabricated and the 
height of MWNTs was ~ 2 µm (inset). Then, pyrrole was electoro-deposited on 
MWNTs, leading to polypyrrole (PPy)-coated MWNTs. Because conducting 
polymer (e.g. PPy) has biocompatibility and electrochemical characteristics, it is 
widely used as a coating material for electrode of neural prosthetic device [103]. It 
is well known that MWNTs/conducing polymer composites have several 
advantages, such as low impedance of electrode, fast charge transfer, high 
capacitance, and enhanced mechanical stability [104]. Therefore, these 
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MWNTs/conducting polymer composited electrodes were used as neural prosthetic 
devices to improve neuronal recording. 
Motivated by the properties of MWNTs/conducting polymer composited 
electrodes, I apply these electrodes to the capacitance imaging. The morphology of 
PPy-coated MWNTs electrodes is important to reduce contact resistance between 
electrodes and atherosclerotic plaque tissue. The SEM images of before (Figure 
61a) and after (Figure 61b) electrodeposited pyrrole on MWNTs show that PPy 
was well coated on MWNTs. The SEM study suggests that PPy possibly acted as 
support fixture to improve mechanical strength of MWNTs, leading to enhance the 
stability of electrodes. The optical image shows that PPy-coated MWNTs (30 µm 
in diameter, black color) was fabricated on Pt electrodes (Figure 60c). We also used 
conventional TiN-MEA to compare the performance of capacitance imaging with 
PPy-MWNTs-MEA (Figure 60d). 
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Figure 60. (a) Schematic diagram of fabrication of PPy-MWNTs-MEA. (b) SEM 
image of the cross-section of the PPy-MWNTs-MEA. White arrows indicate PPy-
MWNTs grown on Pt electrode. The inset shows magnified cross-section image of 
the PPy-MWNTs grown on Pt electrode. Optical microscope (OM) images of the (c) 
PPy-MWNTs-MEA and (d) TiN-MEA. 
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Figure 61. SEM images of before (a) and after (b) electrodeposited pyrrole on 
MWNTs.  
 
 
4.3.2. Ex vivo contact impedance 
 
An atherosclerotic plaque tissue was obtained from female apoE-/- mice with 
a high fat diet (ApoE-/- HFD) during 4 weeks. Dissected aorta ex vivo tissue 
(Figure 62) then stained with Oil Red O (ORO) to visualize lipid region. I have 
confirmed that the lipids contents were high in arch investigated by in vivo 
imaging system (IVIS) as well as ORO staining. This aorta arch was mounted on 
the two types of MEA; PPy-MWNTs-MEA and TiN-MEA and measured contact 
impedance under an ac voltage of 10 mV at a frequency of 100 kHz using LCR 
meter (Figure 63). Then, the contact impedance images were plotted on a 120 color 
scale with blue color denoting the lowest impedance (Figure 64a). I found that the 
use of PPy-MWNTs-MEA decreased the contact impedance by a factor of ~6 as 
compared to TiN-MEA as shown in Figure 64b. The reduction of contact 
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impedance is due to the high conductivity, high surface area, and increased 
mechanical stability of PPy-MWNTs-MEA. From this result, I anticipate that it is 
possible to visualize of lipid region in arch more apparently using PPy-MWNTs-
MEA compared to TiN-MEA. 
 
 
 
Figure 62. Photograph of the atherosclerotic plaque tissue dissected from the  
apoE-/-
 
 HFD mouse. The atherosclerotic plaque tissue was fixed by formaldehyde 
before ORO staining. 
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Figure 63. Schematic of the measurement system. The 60 electrodes of the PPy-
MWNTs-MEA (or 59 electrodes of the TiN-MEA) were connected to the LCR 
meter. In PPy-MWNTs-MEA, an Ag/AgCl electrode was used as reference 
electrode.  
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Figure 64. (a) The ex vivo contact impedance between electrodes (PPy-MWNTs-
MEA or TiN-MEA) and atherosclerotic plaque tissue measured at 100 kHz. (b) The 
average ex-vivo contact impedance measured at 100 kHz for the two types of 
electrodes; PPy-MWNTs-MEA and TiN-MEA (n = 20 electrodes). 
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4.3.3. Discrimination of lipid region in atherosclerotic plaque tissue 
 
Next, I investigated whether capacitance imaging technique can be used to 
discriminate lipid region from lipid-free region. For this, ORO stained arch was 
mounted on the two types of MEA as previously mentioned above. As I mentioned 
in introduction, the lipid region in arch obtained from ApoE-/- 
The capacitance measurements at 10 kHz were plotted on a 120 color scale 
with red color denoting the highest capacitance. Comparison with the ORO-stained 
area in optical microscope (OM) images revealed that the red region with higher 
capacitance values which is measured by PPy-MWNTs-MEA corresponded to the 
lipid region. In TiN-MEA, however, the red color region indicating higher 
capacitance values was not seen at all, which means that TiN-MEA could not 
discriminate lipid region (Figure 65). 
HFD has different 
dielectric constant (ε) compared with lipid-free region (Figure 59). Therefore, 
discrimination between lipid region and lipid-free region could be enabled by 
capacitance imaging technique. 
 
 
 
 
 
- 148 - 
 
 
Figure 65. Optical microscope (OM) and capacitance images of the ORO-stained 
atherosclerotic plaque tissue. The ORO-stained atherosclerotic plaque tissue (red 
area in OM image, square box) was located on the PPy-MWNTs-MEA or TiN-
MEA. For the capacitance imaging, an input AC voltage of 10 mV and frequency 
at 10 kHz were applied to the atherosclerotic plaque tissue. The color range was set 
between 0.20 and 0.90 nF with the red color denoting the highest capacitance and 
the gray circle denoting the electrode. The red region in the capacitance images 
measured by PPy-MWNTs-MEA corresponds to the ORO-stained area in OM 
images. 
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The frequency dependence of the capacitance and phase measured using 
PPy-MWNTs-MEA is shown in Figure 66 for the lipid region or lipid-free region 
in Figure 65. The lipid region represents an increase in capacitance over the entire 
frequency range (10 ~ 100 kHz), accompanied by a decrease in phase at the below 
60 kHz, indicating lipid region has more capacitive property than lipid-free region. 
The trend of phase is comparable to previously studies reported by other groups 
[101]. These results indicated that PPy-MWNTs-MEA yields more apparent 
capacitance imaging of lipid region in arch than TiN-MEA, which is ascribe to 
improved contacts between the PPy-MWNTs and the arch. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
- 150 - 
 
 
 
 
 
Figure 66. Frequency dependence of the capacitance (left Y-axis) and phase (right 
Y-axis) measured at lipid region (ORO-stained) or lipid-free region using the PPy-
MWNTs-MEA. At the lipid region, the capacitance increased over the entire 
frequency range from 10 to 100 kHz compared to the lipid-free region, 
accompanied by a decrease in phase at a frequency below 60 kHz, indicating a 
more capacitive property than the lipid-free region (filled symbols : capacitance, 
opened symbols : phase, n = 3). 
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To investigate whether the lipid region of arch can be detected by flexible 
MEA, I also fabricated SWNTs-based flexible MEA (F-MEA). The SWNTs with 
percolating structures can provide a large effective surface area and mechanical 
flexible, enabling enhanced interfacing with atherosclerotic plaque tissue. The 
fabricated F-MEA has flexibility (Figure 67a) and percolating structures (Figure 
67b). Capacitance imaging was performed by in two cases, a flat MEA (r = 0 cm) 
and a curved MEA (r = 1.5 cm), as shown in Figure 68a. Then, the ORO-stained 
arch was placed on F-MEA (Figure 67c). The capacitance measurements at 500 Hz 
were plotted on a 120 color scale with red color denoting the highest capacitance 
under the two conditions (r = 0 cm and r = 1.5 cm). In F-MEA, the capacitance 
values were lowered than PPy-MWNTs-MEA due to the semiconducting SWNTs 
of unsorted SWNTs (2/3 semiconducting, 1/3 metallic). Nevertheless, the lipid 
region could be detected by F-MEA even though the ability of distinguishing lipid 
region was slightly decreased in curved MEA (r = 1.5 cm). 
The frequency dependence of the capacitance and phase measured using 
curved MEA (r = 1.5 cm) shows similar results as mentioned above (i.e. lipid 
region has more capacitive property than lipid-free region) (Figure 68b). Therefore, 
I could demonstrate the feasibility of F-MEA for identification of lipid in 
atherosclerotic plaque tissue. Further study of optimized conditions in F-MEA is 
needed. 
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Figure 67. (a) The photograph of SWNTs-based electrodes on flexible substrate (F-
MEA). (b) SEM image of SWNTs electrodes. Enlarged SWNTs electrode image 
was also indicated (blue dot circle). (c) The OM image of ORO-stained 
atherosclerotic plaque tissue (red area in OM image, red dot line) which was 
mounted on F-MEA. (d) Capacitance imaging of the lipid in atherosclerotic plaque 
tissue was obtained using F-MEA (r = 0 cm or r = 1.5 cm) under an input AC 
voltage of 10 mV and frequency at 500 Hz. The color range was set between 0 and 
0.90 nF with the red color denoting the highest capacitance and the gray circle 
denoting the electrode. 
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Figure 68. (a) The photograph of F-MEA (r = 0 cm or r = 1.5 cm), (b) Frequency 
dependence of the capacitance (left Y-axis) and phase (right Y-axis) measured at 
lipid region (ORO-stained) or lipid-free region using the F-MEA (r = 1.5 cm). At 
the lipid region, the capacitance increased over the entire frequency range from 500 
to 2900 Hz compared to the lipid-free region, accompanied by a decrease in phase 
at a frequency, demonstrating a more capacitive property than the lipid-free region 
(filled symbols : capacitance, opened symbols : phase, n = 3).  
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4.4. Summary 
 
I have developed a capacitance imaging technique using PPy-MWNTs-MEA 
or F-MEA. The lipid in atherosclerotic plaque tissue, which is derived from an 
apolipoprotein-E receptor-deficient (apoE-/-
 
) mouse, exhibit higher capacitance 
than the lipid-free region, allowing the capacitance imaging of lipid region in 
atherosclerosis. Compared to TiN-MEA, PPy-MWNTs-MEA yields more distinct 
and high resolution capacitance imaging of lipid region in atherosclerotic plaque 
tissue, which is ascribe to improved contacts between the PPy-MWNTs and the 
atherosclerotic plaque tissue. I also demonstrate that flexible electrodes can detect 
lipid region under curved condition, which is applicable to stent-based 
atherosclerosis sensing in clinic. 
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ABSTRACT in Korean 
 
약물이 담지된 금 플라스모닉  
나노입자를 이용한 다-약물 내성암과  
류마티스 관절염 치료 
 
 
약물이 담지된 polylactic-co-glycolic acid (PLGA) 고분자에 반구 
형태의 금 박막 및 철 박막을 입혀, in vitro 및 in vivo 에서 다-약물 내
성 암과 류마티스 관절염을 치료할 수 있는 금 플라스모닉 나노입자를 
제작하였다. 약물이 담지된 금 플라스모닉 나노입자는 고유한 특징을 보
이는데, 나노입자의 반쪽 부분에서는 약물이 방출되고, 나노입자의 나머
지 반쪽 부분은 금 박막 또는 철 박막으로 구성되어 있어 근적외선 및 
자기공명 영상에 사용될 수 있고, 근적외선 레이져를 조사 하였을 때, 
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금 박막에서 발생하는 열을 이용해 고분자 안에 담지되어 있는 약물의 
방출을 증가시킬 수 있다. 또한, 금 박막은 표면 처리가 쉽기 때문에 다
양한 항체 및 표적지향물질을 결합시킬 수 있다. 
본 연구에서는 먼저 다-약물 내성 암을 치료하고자 했는데, 일반적
으로 다-약물 내성 암은 P-glycoprotein 과 같은 배출 단백질 (efflux 
protein)이 과 발현 되어 있기 때문에 세포 안으로 들어온 약물을 빠르
게 세포 밖으로 배출하게 된다. 따라서 다-약물 내성 암을 효과적으로 
치료하기 위해서는 배출 단백질의 기능을 억제시키는 것이 가장 중요하
다. 항암제인 독소루비신 (Doxorubicin, DOX)를 담지하고, 독소루비신에 
내성이 있는 결장 종양세포 (DLD-1/DOX)와 선택적으로 반응하는 항체 
(Human TRAIL R1/TNFRSF10A Antibody, Anti-DR4)가 금 박막에 결
합되어 있는 나노입자의 광열 효과 (Photothermal Effect)를 이용해 다-
약물 내성 암을 효과적으로 치료하였다.  
현재까지 나노입자를 이용한 치료는 주로 암을 목표로 연구가 많
이 진행되었는데, 만성 염증성 관절염인 류마티스 관절염에서도 약물이 
담지된 금 플라스모닉 나노입자의 치료효과가 있는지 연구하였다. 류마
티스 관절염 치료제인 메토트렉세이트 (Methotrexate, MTX)를 담지하
고, 염증 표적지향물질인 arginine-glycine-aspartic acid (RGD) 펩타이
드 (peptides)가 금 박막에 결합되어 있는 나노입자를 이용해 류마티스 
관절염 역시 효과적으로 치료되는 것을 확인하였다. 또한, 금 박막 사이
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에 철 박막을 입힌 후, 네오듐 (Nd) 자석을 이용하여 관절염 부위에 나
노입자가 오래 머무르도록 함으로서, 좀더 효과적인 광열 및 화학적 치
료효과 뿐 만 아니라, 자기공명영상 (MRI, Magnetic resonance image)
을 얻을 수 있었다. 
 
 
 
 
 
 
핵심어 : 약물이 담지된 금 플라스모닉 나노입자, 약물이 담지된 금/철/
금 플라스모닉 나노입자, 화학적-광열 치료, 광열로 조절되는 약물 전달, 
다-약물 내성암, 류마티스 관절염 
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